Ioannis Parodis

About me
Publications
CV
Public outreach and news

About me

MD PhD

Senior consultant rheumatologist | Associate Professor of Rheumatology

Research area: Clinical and translational research within the field of inflammation and autoimmunity

I studied medicine at the National and Kapodistrian University of Athens, Greece, and graduated in 2006. I have an interest in B cell biology and novel treatments for systemic lupus erythematosus and lupus nephritis. My research has focused on identifying biomarkers and calibrating predictive models for diagnostics, clinical and immune responses to therapies, and long-term prognosis in systemic lupus erythematosus and lupus nephritis.

Research

The goal of our research is to contribute to improved surveillance and management for people living with systemic lupus erythematosus. We focus on
identification of biomarkers that reflect activity and portend flare, response or non-response to therapy, particularly B cell targeted biologics, and long-term outcome. We stress on patient-reported health status and patient participation in medical care.

Last but not least, we have projects within medical pedagogy, and we are currently working on the development of a novel virtual patient modality for
enhancing the acquirement of clinical reasoning skills and for facilitating interprofessional learning.

Teaching

Past doctoral students

Serving as main supervisor:
- Shahrzad Kia Komujuni (Karolinska Institutet)
Current doctoral students

Serving as main supervisor:
- Alvaro Gomez Gonzalez (Karolinska Institutet)
- Julius Lindblom (Karolinska Institutet)
- Alexander Borg (Karolinska Institutet)
- Sandra Jägerback (Karolinska Institutet)
Serving as co-supervisor:
- Tomas Walhelm (Linköping University)
- Kinza Degerlund Maldi (Karolinska Institutet)

Articles

Article: RHEUMATOLOGY. 2025;64(2):623-631
Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab
Jagerback S; Gomez A; Parodis I
Article: RHEUMATOLOGY. 2025;64(2):639-647
Lupus Low Disease Activity State and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-up
Parodis I; Haugli-Stephens T; Dominicus A; Eek D; Sjoewall C
Article: RHEUMATOLOGY. 2025;64(2):597-606
Characteristics and risk factors of COVID-19 breakthrough infections in Idiopathic Inflammatory Myopathies: Results from the COVAD study
Hoff LS; Naveen R; Sen P; Day J; Joshi M; Nune A; Nikiphorou E; Saha S; Tan AL; Shinjo SK; Ziade N; Velikova T; Milchert M; Jagtap K; Parodis I; Edgar Gracia-Ramos A; Cavagna L; Kuwana M; Knitza J; Chen YM; Makol A; Agarwal V; Patel A; Pauling JD; Wincup C; Barman B; Zamora Tehozol EA; Rojas Serrano J; Garcia-De La Torre I; Colunga-Pedraza IJ; Merayo-Chalico J; Chibuzo OC; Katchamart W; Akarawatcharangura Goo P; Shumnalieva R; El Kibbi L; Halabi H; Vaidya B; Shaharir SS; Hasan ATMT; Dey D; Toro Gutierrez CE; Caballero-Uribe CV; Lilleker JB; Salim B; Gheita T; Chatterjee T; Distler O; Saavedra MA; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Journal article: LANCET RHEUMATOLOGY. 2024;:S2665-9913(24)00351-5
Promise and challenges of mesenchymal stromal cell therapy in severe SLE.
Parodis I
Article: RHEUMATOLOGY INTERNATIONAL. 2024;44(12):3041-3051
Enhancing clinical reasoning skills for medical students: a qualitative comparison of LLM-powered social robotic versus computer-based virtual patients within rheumatology
Borg A; Jobs B; Huss V; Gentline C; Espinosa F; Ruiz M; Edelbring S; Georg C; Skantze G; Parodis I
Article: LANCET RHEUMATOLOGY. 2024;6(11):e751-e761
Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials
Parodis I; Lindblom J; Levy RA; Zen M; Cetrez N; Gomez A; Oon S; Henning C; Khamashta M; Quasny HA; Chauhan D; Askanase A; van Vollenhoven R; Nikpour M
Article: SEMINARS IN ARTHRITIS AND RHEUMATISM. 2024;68:152520
OMERACT systemic lupus erythematosus domain survey
Nielsen W; Strand V; Simon L; Pinsker E; Bonilla D; Morand E; Thumboo J; Aringer M; Mosca M; Bruce I; Parodis I; Kim A; Desai M; Enman Y; Shea B; Wallace DJ; Chaichian Y; Navarra S; Aranow C; Mackay M; Trotter K; Tayer-Shifman OE; Duarte-Garcia A; Tam LS; Ugarte-Gil MF; Pons-Estel GJ; Reynolds JA; Nikpour M; Hoi A; Romero-Diaz J; Aggarwal A; Mok CC; Fujio K; Ramsey-Goldman R; Gladman DD; Arnaud L; Bultink IEM; Ruiz-Irastorza G; Ines LS; Appenzeller S; Dobrowolski C; Clarke AE; Kamen DL; Barraclough M; Tani C; Gomez-Puerta J; Werth VP; Katz P; Nowrouzi-Kia B; Johnson SR; Drucker AM; Touma Z
Article: RHEUMATOLOGY INTERNATIONAL. 2024;44(10):1923-1933
Breakthrough SARS-CoV-2 infection in fully vaccinated patients with systemic lupus erythematosus: results from the COVID-19 Vaccination in Autoimmune Disease (COVAD) study
Palazzo L; Lindblom J; Olsson EK; Nikiphorou E; Wincup C; Saha S; Shaharir SS; Katchamart W; Goo PA; Traboco L; Chen Y-M; Lilleker JB; Nune A; Pauling JD; Agarwal V; Dzifa D; Gutierrez CET; Caballero-Uribe CV; Chinoy H; Agarwak V; Gupta L; Parodis I
Article: JOURNAL OF IMMUNOLOGICAL METHODS. 2024;532:113717
Belimumab concentration measurements using a homologous anti-idiotype immunoassay
Loeff FC; Parodis I; Walhelm T; Jonsen A; Nikolopoulos D; Sjowall C; Bengtsson AA; Kos D; van Leeuwen A; van den Broek B; Dijk L; Jeremiasse J; Blomjous BS; Voskuyl AE; Wolbink GJ; Bultin IEM; Rispens T
Article: RHEUMATOLOGY INTERNATIONAL. 2024;44(9):1679-1689
Neuropsychiatric involvement in systemic lupus erythematosus contributes to organ damage beyond the nervous system: a post-hoc analysis of 5 phase III randomized clinical trials
Nikolopoulos D; Cetrez N; Lindblom J; Parodis I
Article: RHEUMATOLOGY. 2024;63(9):2494-2502
Patients with NPSLE experience poorer HRQoL and more fatigue than SLE patients with no neuropsychiatric involvement, irrespective of neuropsychiatric activity
Nikolopoulos D; Cetrez N; Lindblom J; Palazzo L; Enman Y; Parodis I
Article: ANNALS OF THE RHEUMATIC DISEASES. 2024;83(9):1132-1143
Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events
Nikolopoulos D; Loukogiannaki C; Sentis G; Garantziotis P; Manolakou T; Kapsala N; Nikoloudaki M; Pieta A; Flouda S; Parodis I; Bertsias G; Fanouriakis A; Filia A; Boumpas DT
Article: RHEUMATOLOGY AND THERAPY. 2024;11(4):897-911
Cardiovascular Risk Evaluation in Psoriatic Arthritis by Aortic Stiffness and the Systemic Coronary Risk Evaluation (SCORE): Results of the Prospective PSOCARD Cohort Study
Triantafyllias K; Liverakos S; Muthuraman M; Cavagna L; Parodis I; Schwarting A
Article: MODERN RHEUMATOLOGY. 2024;34(4):756-766
Gender differences in patient experience in idiopathic inflammatory myopathies: Subanalysis from the COVAD dataset
Yoshida A; Kim M; Kuwana M; Ravichandran N; Makol A; Sen P; Lilleker JB; Agarwal V; Kardes S; Day J; Milchert M; Joshi M; Gheita T; Salim B; Velikova T; Gracia-Ramos AE; Parodis I; Nikiphorou E; Chatterjee T; Tan AL; Nune A; Cavagna L; Saavedra MA; Shinjo SK; Ziade N; Knitza J; Distler O; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Article: RHEUMATOLOGY INTERNATIONAL. 2024;44(7):1233-1244
Collating the voice of people with autoimmune diseases: Methodology for the Third Phase of the COVAD Studies
Kadam E; Javaid M; Sen P; Saha S; Ziade N; Day J; Wincup C; Andreoli L; Parodis I; Tan AL; Shinjo SK; Dey D; Cavagna L; Chatterjee T; Knitza J; Wang G; Dalbeth N; Velikova T; Battista S; Cheng K; Boyd P; Kobert L; Gracia-Ramos AE; Mittal S; Makol A; Gutierrez CET; Uribe CVC; Kuwana M; Burmester G-R; Guillemin F; Nikiphorou E; Chinoy H; Aggarwal V; Gupta L
Article: ANNALS OF THE RHEUMATIC DISEASES. 2024;83(7):889-900
Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort
Parodis I; Lindblom J; Barturen G; Ortega-Castro R; Cervera R; Pers J-O; Genre F; Hiepe F; Gerosa M; Kovacs L; De Langhe E; Piantoni S; Stummvoll G; Vasconcelos C; Vigone B; Witte T; Alarcon-Riquelme ME; Beretta L
Article: KIDNEY INTERNATIONAL REPORTS. 2024;9(6):1817-1835
Interferon and B-cell Signatures Inform Precision Medicine in Lupus Nephritis
Parodis I; Lindblom J; Toro-Dominguez D; Beretta L; Borghi MO; Castillo J; Carnero-Montoro E; Enman Y; Mohan C; Alarcon-Riquelme ME; Barturen G; Nikolopoulos D; PRECISESADS Clinical Consortium OBOPREC
Article: ANNALS OF THE RHEUMATIC DISEASES. 2024;83(6):720-729
EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis
Parodis I; Girard-Guyonvarc'h C; Arnaud L; Distler O; Domjan A; Van den Ende CHM; Fligelstone K; Kocher A; Larosa M; Lau M; Mitropoulos A; Ndosi M; Poole JL; Redmond A; Ritschl V; Alexanderson H; Sjoberg Y; von Perner G; Uhlig T; Varju C; Vriezekolk JE; Welin E; Westhovens R; Stamm TA; Bostrom C
Article: RHEUMATOLOGY. 2024;63(5):1341-1351
COVID-19 vaccine safety during pregnancy and breastfeeding in women with autoimmune diseases: results from the COVAD study
Andreoli L; Lini D; Schreiber K; Parodis I; Sen P; Ravichandran N; Day J; Joshi M; Jagtap K; Nune A; Nikiphorou E; Agarwal V; Saha S; Tan AL; Shinjo SK; Ziade N; Velikova T; Milchert M; Gracia-Ramos AE; Cavagna L; Kuwana M; Knitza J; Makol A; Patel A; Pauling JD; Wincup C; Barman B; Tehozol EAZ; Serrano JR; de la Torre IG; Colunga-Pedraza IJ; Merayo-Chalico J; Chibuzo OC; Katchamart W; Akarawatcharangura Goo P; Shumnalieva R; Chen Y-M; Hoff LS; El Kibbi L; Halabi H; Vaidya B; Shaharir SS; Hasan ATMT; Dey D; Gutierrez CET; Caballero-Uribe CV; Lilleker JB; Salim B; Gheita T; Chatterjee T; Saavedra MA; Distler O; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Article: RHEUMATOLOGY INTERNATIONAL. 2024;44(5):851-861
Obesity and tobacco smoking are independently associated with poor patient-reported outcomes in SLE: a cross-sectional study
Gomez A; Parodis I; Sjowall C
Article: INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES. 2024;27(5):e15178
Characteristics of emerging new autoimmune diseases after COVID-19 vaccination: A sub-study by the COVAD group
Shumnalieva R; Ravichandran N; Hannah J; Javaid M; Darooka N; Roy D; Gonzalez DE; Velikova T; Milchert M; Kuwana M; Joshi M; Gracia-Ramos AE; Boyd P; Yaadav P; Cheng K; Kobert L; Cavagna L; Sen P; Day J; Makol A; Gutierrez CET; Caballero-Uribe CV; Saha S; Parodis I; Dey D; Nikiphorou E; Distler O; Kadam E; Tan AL; Shinjo SK; Ziade N; Knitza J; Chinoy H; Aggarwal R; Agarwal V; Gupta L
Article: INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES. 2024;27(5):e15161
Listening to patients, for the patients: The COVAD Study-Vision, organizational structure, and challenges
Joshi M; Darooka N; Saha S; Dyball S; Sen P; Yaadav P; Javaid M; Kadam E; Shinjo SK; Dey D; Cavagna L; Makol A; Gutierrez CET; Caballero Uribe CV; Kuwana M; Burmester G-R; Ziade N; Wincup C; Andreoli L; Parodis I; Tan AL; Guillemin F; Knitza J; Wang G; Dalbeth N; Velikova T; Gracia-Ramos AE; Nikiphorou E; Day J; Chinoy H; Aggarwal R; Agarwal V; Gupta L
Article: LUPUS. 2024;33(6):615-628
Factors associated with non-adherence to medications in systemic lupus erythematosus: Results from a Swedish survey
Emamikia S; Gomez A; Adahl T; von Perner G; Enman Y; Chatzidionysiou K; Arkema EV; Parodis I
Article: RMD OPEN. 2024;10(2):e004171
Recommendations for physical activity and exercise in persons living with Systemic Lupus Erythematosus (SLE): consensus by an international task force
Blaess J; Geneton S; Goepfert T; Appenzeller S; Bordier G; Davergne T; Fuentes Y; Haglo H; Hambly K; Kinnett-Hopkins D; Su K-Y; Legge A; Li L; Mak A; Padjen I; Sciascia S; Sheikh SZ; Soriano-Maldonado A; Ugarte-Gil MF; Yusof MYM; Parodis I; Arnaud L
Article: SEMINARS IN ARTHRITIS AND RHEUMATISM. 2024;65:152380
OMERACT 2023 Systemic Lupus Erythematosus Special Interest Group: Winnowing and Binning Preliminary Candidate Domains for the Core Outcome Set
Nielsen W; Strand V; Simon LS; Parodis I; Kim AHJ; Desai M; Enman Y; Wallace D; Chaichian Y; Navarra S; Aranow C; MacKay M; Trotter K; Tayer-Shifman OE; Duarte-Garcia A; Tam LS; Ugarte-Gil MF; PonsEstel GJ; Reynolds JA; Nikpour M; Hoi A; Romero-Diaz J; Papachristos D; Aggarwal A; Mok CC; Fujio K; Ramsey-Goldman R; Howe A; Kia BN; Bonilla D; Thumboo J; Mosca M; Aringer M; Johnson SR; Drucker AM; Morand E; Bruce I; Touma Z
Article: RHEUMATOLOGY ADVANCES IN PRACTICE. 2024;8(2):rkae028
Impaired health-related quality of life in idiopathic inflammatory myopathies: a cross-sectional analysis from the COVAD-2 e-survey
Yoshida A; Li Y; Maroufy V; Kuwana M; Sazliyana Shaharir S; Makol A; Sen P; Lilleker JB; Agarwal V; Kadam E; Akawatcharangura Goo P; Day J; Milchert M; Chen Y-M; Dey D; Velikova T; Saha S; Edgar Gracia-Ramos A; Parodis I; Nikiphorou E; Tan AL; Nune A; Cavagna L; Toro Gutierrez CE; Caballero-Uribe CV; Saavedra MA; Shinjo SK; Ziade N; El Kibbi L; Knitza J; Distler O; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Article: JOURNAL OF CLINICAL MEDICINE. 2024;13(5):1485
Factors Associated with Survival and Discontinuation of Anti-Malarial Agents in Systemic Lupus Erythematosus: Results from a Tertiary Swedish Referral Centre
Walhelm T; Wirestam L; Enman Y; Parodis I; Sjowall C
Article: RHEUMATOLOGY. 2024;63(3):657-664
Global disparities in the treatment of idiopathic inflammatory myopathies: results from an international online survey study
Ziade N; Aoude M; Hmamouchi I; Naveen R; Lilleker JB; Sen P; Joshi M; Agarwal V; Kardes S; Day J; Makol A; Milchert M; Gheita T; Salim B; Velikova T; Edgar Gracia-Ramos A; Parodis I; Nikiphorou E; Chatterjee T; Tan AL; Saavedra MA; Shinjo SK; Knitza J; Kuwana M; Nune A; Cavagna L; Distler O; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Article: RHEUMATOLOGY. 2024;63(3):798-808
Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase III trials of belimumab
Palazzo L; Lindblom J; Cetrez N; Ala H; Parodis I
Article: RHEUMATOLOGY. 2024;63(2):338-348
Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials
Gomez A; Jagerback S; Sjowall C; Parodis I
Article: RHEUMATOLOGY. 2024;63(1):127-139
Flares in IIMs and the timeline following COVID-19 vaccination: a combined analysis of the COVAD-1 and-2 surveys
Naveen P; Sen P; Griger Z; Day J; Joshi M; Nune A; Nikiphorou E; Saha S; Tan AL; Shinjo SK; Ziade N; Velikova T; Milchert M; Jagtap K; Parodis I; Gracia-Ramos AE; Cavagna L; Kuwana M; Knitza J; Chen YM; Makol A; Agarwal V; Patel A; Pauling JD; Wincup C; Barman B; Zamora Tehozol EA; Rojas Serrano J; Garcia-De La Torre I; Colunga-Pedraza IJ; Merayo-Chalico J; Chibuzo OC; Katchamart W; Akarawatcharangura Goo P; Shumnalieva R; Hoff LS; El Kibbi L; Halabi H; Vaidya B; Shaharir SS; Hasan ATMT; Dey D; Toro Gutierrez CE; Caballero-Uribe CV; Lilleker JB; Salim B; Gheita T; Chatterjee T; Distler O; Saavedra MA; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Article: ANNALS OF THE RHEUMATIC DISEASES. 2024;83(1):15-29
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Fanouriakis A; Kostopoulou M; Andersen J; Aringer M; Arnaud L; Bae S-C; Boletis J; Bruce IN; Cervera R; Doria A; Doerner T; Furie RA; Gladman DD; Houssiau FA; Ines LS; Jayne D; Kouloumas M; Kovacs L; Mok CC; Morand EF; Moroni G; Mosca M; Mucke J; Mukhtyar CB; Nagy G; Navarra S; Parodis I; Pego-Reigosa JM; Petri M; Pons-Estel BA; Schneider M; Smolen JS; Svenungsson E; Tanaka Y; Tektonidou MG; Teng YKO; Tincani A; Vital EM; van Vollenhoven RF; Wincup C; Bertsias G; Boumpas DT
Article: RHEUMATOLOGY INTERNATIONAL. 2024;44(1):73-80
COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group
Panchawagh S; Ravichandran N; Barman B; Nune A; Javaid M; Gracia-Ramos AE; Day J; Joshi M; Kuwana M; Saha S; Pande AR; Caballero-Uribe CV; Velikova T; Parodis I; Knitza J; Kadam E; Tan AL; Shinjo SK; Boro H; Aggarwal R; Agarwal V; Chatterjee T; Gupta L
Article: JOURNAL OF DIABETES INVESTIGATION. 2024;15(1):131-138
Type 1 diabetes, COVID-19 vaccines and short-term safety: Subgroup analysis from the global COVAD study
Chatterjee T; Ravichandran N; Nair N; Gracia-Ramos AE; Barman B; Sen P; Joshi M; Saha S; Nune A; Pande AKR; Velikova T; Parodis I; Tan AL; Shinjo SK; Boro H; Agarwal V; Aggarwal R; Gupta L
Article: RHEUMATOLOGY INTERNATIONAL. 2024;44(1):89-97
Correlates of breakthrough COVID-19 in vaccinated patients with systemic sclerosis: survival analysis from a multicentre international patient-reported survey
Ahmed S; Gupta L; Kuwana M; Pauling JD; Day J; Ravichandran N; Joshi M; Parodis I; Sen P; Jagtap K; Nikiphorou E; Saha S; Agarwal V; Chatterjee T; Lilleker JB; Kardes S; Milchert M; Gheita T; Salim B; Velikova T; Gracia-Ramos AE; Tan AL; Nune A; Cavagna L; Saavedra MA; Shinjo SK; Ziade N; Knitza J; Distler O; Wibowo SAK; Barman B; Singh YP; Ranjan R; Jain A; Pandya SC; Pilania RK; Sharma A; Manoj MM; Gupta V; Kavadichanda CG; Patro PS; Ajmani S; Phatak S; Goswami RP; Chowdhury AC; Mathew AJ; Shenoy P; Asranna A; Bommakanti KT; Shukla A; Pande AR; Chandwar K; Cansu DU; Wincup C; Del Papa N; Sambataro G; Fabiola A; Govoni M; Parisi S; Bocci EB; Sebastiani GD; Fusaro E; Sebastiani M; Quartuccio L; Franceschini F; Sainaghi PP; Orsolini G; De Angelis R; Danielli MG; Venerito V; Traboco LS; Serrano JR; La Torre IG-D; Tehozol EAZ; Loarce-Martos J; Prieto-Gonzalez S; Gil-Vila A; Gonzalez RA; Yoshida A; Nakashima R; Sato S; Kimura N; Kaneko Y; Tomaras S; Gromova MA; Aharonov O; Hmamouchi I; Hoff LS; Giannini M; Maurier F; Campagne J; Meyer A; Nagy-Vincze M; Langguth D; Limaye V; Needham M; Srivastav N; Hudson M; Landon-Cardinal O; Shaharir SS; Zuleta WGR; Silva JAP; Fonseca JE; Zimba O; Chinoy H; Aggarwal R; Agarwal V; Makol A
Article: AUTOIMMUNITY REVIEWS. 2024;23(1):103422
Is per-protocol kidney biopsy required in lupus nephritis?
Parodis I; Moroni G; Calatroni M; Bellis E; Gatto M
Article: AUTOIMMUNITY REVIEWS. 2024;23(1):103418
When should targeted therapies be used in the treatment of lupus nephritis: Early in the disease course or in refractory patients?
Parodis I; Depascale R; Doria A; Anders H-J
Article: JOURNAL OF CLINICAL MEDICINE. 2023;12(24):7542
COVID-19 Vaccination-Related Delayed Adverse Events among Patients with Systemic Lupus Erythematosus
Dey M; Doskaliuk B; Lindblom J; Nikiphorou E; Wincup C; Fathima M; Saha S; Shaharir SS; Katchamart W; Goo PA; Traboco L; Chen Y-M; Kadam E; Lilleker JB; Nune A; Pauling JD; Agarwal V; Dey D; Toro Gutierrez CE; Caballero CV; Chinoy H; Aggarwal R; Agarwal V; Gupta L; Parodis I
Article: RHEUMATOLOGY. 2023;62(12):3838-3848
Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period-a cross-sequential study based on COVAD surveys
Jagtap K; Naveen R; Day J; Sen P; Vaidya B; Nune A; Nikiphorou E; Tan AL; Agarwal V; Saha S; Shinjo SK; Ziade N; Joshi M; Velikova T; Milchert M; Parodis I; Edgar Gracia-Ramos A; Cavagna L; Kuwana M; Knitza J; Makol A; Patel A; Pauling JD; Wincup C; Barman B; Zamora Tehozol EA; Rojas Serrano J; Garcia-De La Torre I; Colunga-Pedraza IJ; Merayo-Chalico J; Chibuzo OC; Katchamart W; Goo PA; Shumnalieva R; Chen Y-M; Hoff LS; El Kibbi L; Halabi H; Sazliyana Shaharir S; Hasan ATMT; Dey D; Gutierrez CET; Caballero-Uribe CV; Lilleker JB; Salim B; Gheita T; Chatterjee T; Saavedra MA; Distler O; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Article: RHEUMATOLOGY. 2023;62(12):3916-3923
Sensitivity analysis of EQ-5D-3L index scores in terms of discriminative and known-groups validity in SLE: introducing Adequate Health State
Hua N; Gomez A; Lindblom J; Emamikia S; Enman Y; Grannas D; Heintz E; Regardt M; Parodis I
Article: BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY. 2023;37(4):101894
Reframing health disparities in SLE: A critical reassessment of racial and ethnic differences in lupus disease outcomes
Parodis I; Lanata C; Nikolopoulos D; Blazer A; Yazdany J
Article: RHEUMATOLOGY. 2023;62(10):3291-3301
Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys
Sen P; Naveen R; Houshmand N; Kia SM; Joshi M; Saha S; Jagtap K; Agarwal V; Nune A; Nikiphorou E; Tan AL; Shinjo SK; Ziade N; Velikova T; Milchert M; Parodis I; Gracia-Ramos AE; Cavagna L; Kuwana M; Knitza J; Makol A; Patel A; Pauling JD; Wincup C; Barman B; Tehozol EAZ; Serrano JR; de la Torre I; Colunga-Pedraza IJ; Merayo-Chalico J; Chibuzo OC; Katchamart W; Akawatcharangura Goo P; Shumnalieva R; Chen Y-M; Hoff LS; El Kibbi L; Halabi H; Vaidya B; Shaharir SS; Hasan ATMT; Dey D; Gutierrez CET; Caballero-Uribe CV; Lilleker JB; Salim B; Gheita T; Chatterjee T; Distler O; Saavedra MA; Day J; Chinoy H; Kardes S; Kardes SA; Andreoli L; Lini D; Screiber K; Vince MN; Singh YP; Ranjan R; Jain A; Pandya SC; Pilania RK; Sharma A; Manoj MM; Gupta V; Kavadichanda CG; Patro PS; Ajmani S; Phatak S; Goswami RP; Chowdhury AC; Mathew AJ; Shenoy P; Asranna A; Bommakanti KT; Shukla A; Pande AR; Chandwar K; Ghodke A; Boro H; Fazal ZZ; Cansu DU; Yildirim R; Gasparyan AY; Del Papa N; Sambataro G; Fabiola A; Govoni M; Parisi S; Bocci EB; Sebastiani GD; Fusaro E; Sebastiani M; Quartuccio L; Franceschini F; Sainaghi PP; Orsolini G; De Angelis R; Danielli MG; Venerito V; Grignaschi S; Giollo A; Alluno A; Ioannone F; Fornaro M; Traboco LS; Wibowo SAK; Loarce-Martos J; Prieto-Gonzalez S; Gonzalez RA; Yoshida A; Nakashima R; Sato S; Kimura N; Kaneko Y; Gono T; Tomaras S; Proft FN; Holzer M-T; Gromova MA; Aharonov O; Griger Z; Hmamouchi I; El Bouchti I; Baba Z; Giannini M; Maurier F; Campagne J; Meyer A; Langguth D; Limaye V; Needham M; Srivastav N; Hudson M; Landon-Cardinal O; Zuleta WGR; Arbelaez A; Cajas J; Silva JAP; Fonseca JE; Zimba O; Bohdana D; Ima-Edomwonyi U; Dedeke I; Airenakho E; Madu NH; Yerima A; Olaosebikan H; Becky A; Koussougbo OD; Palalane E; So H; Ugarte-Gil MF; Chinchay L; Bernaola JP; Pimentel V; Fathi HM; Mohammed RHA; Harifi G; Fuentes-Silva Y; Cabriza K; Losanto J; Colaman N; Cachafeiro-Vilar A; Bautista GG; Ho EJG; Gonzalez R; Nunez LS; Cristian Vergara M; Baez JT; Alonzo H; Pastelin CBS; Salinas RG; Obiols AQ; Chavez N; Ordonez AB; Argueta S; Llerena GAR; Sierra-Zorita R; Arrieta D; Hidalgo ER; Saenz R; Escalante MI; Morales R; Calapaqui W; Quezada I; Arredondo G; Agarwal V; Aggarwal R; Gupta L
Article: RHEUMATOLOGY. 2023;62(9):e263-e268
Flares after COVID-19 infection in patients with idiopathic inflammatory myopathies: results from the COVAD study
Ali SS; Naveen R; Sen P; Day J; Joshi M; Nune A; Nikiphorou E; Saha S; Tan AL; Shinjo SK; Ziade N; Velikova T; Milchert M; Jagtap K; Parodis I; Edgar Gracia-Ramos A; Cavagna L; Kuwana M; Knitza J; Chen YM; Makol A; Agarwal V; Patel A; Pauling JD; Wincup C; Barman B; Zamora Tehozol EA; Rojas Serrano J; La Torre IG-D; Colunga-Pedraza IJ; Merayo-Chalico J; Chibuzo OC; Katchamart W; Goo PA; Shumnalieva R; Hoff LS; El Kibbi L; Halabi H; Vaidya B; Shaharir SS; Hasan ATMT; Dey D; Gutierrez CET; Caballero-Uribe CV; Lilleker JB; Salim B; Gheita T; Chatterjee T; Distler O; Saavedra MA; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Article: RHEUMATOLOGY INTERNATIONAL. 2023;43(9):1651-1664
Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study
Doskaliuk B; Ravichandran N; Sen P; Day J; Joshi M; Nune A; Nikiphorou E; Saha S; Tan AL; Shinjo SK; Ziade N; Velikova T; Milchert M; Jagtap K; Parodis I; Gracia-Ramos AE; Cavagna L; Kuwana M; Knitza J; Chen YM; Makol A; Agarwal V; Patel A; Pauling JD; Wincup C; Barman B; Tehozol EAZ; Serrano JR; Garcia-De La Torre I; Colunga-Pedraza IJ; Merayo-Chalico J; Chibuzo OC; Katchamart W; Goo PA; Shumnalieva R; Hoff LS; Kibbi LE; Halabi H; Vaidya B; Shaharir SS; Hasan ATMT; Dey D; Gutierrez CET; Caballero-Uribe CV; Lilleker JB; Salim B; Gheita T; Chatterjee T; Distler O; Saavedra MA; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Article: RHEUMATOLOGY INTERNATIONAL. 2023;43(9):1637-1649
High fatigue scores in patients with idiopathic inflammatory myopathies: a multigroup comparative study from the COVAD e-survey
Grignaschi S; Kim M; Zanframundo G; Ravichandran N; Lilleker J; Sen P; Joshi M; Agarwal V; Kardes S; Day J; Makol A; Milchert M; Gheita T; Salim B; Velikova T; Gracia-Ramos AE; Parodis I; Nikiphorou E; Chatterjee T; Tan AL; Saavedra M; Shinjo SK; Ziade N; Knitza J; Kuwana M; Nune A; Distler O; Chinoy H; Cavagna L; Agarwal V; Aggarwal R; Gupta L; COVID SG
Article: CLINICAL IMMUNOLOGY. 2023;254:109713
Molecular architecture of proliferative lupus nephritis as elucidated using 50-plex imaging mass cytometry proteomics
Titus ASCLS; Tan Y; Tran P; Lindblom J; Ivbievbiokun M; Xu Y; Zheng J; Parodis I; Cai Q; Chang A; Chen S-H; Zhao M; Mohan C
Article: KIDNEY INTERNATIONAL REPORTS. 2023;8(9):1822-1830
Effect of Belimumab on Preventing de novo Renal Lupus Flares
Parodis I; Lindblom J; Cetrez N; Palazzo L; Ala H; Houssiau FA; Sjoewall C; Rovin BH
Article: JOURNAL OF CLINICAL MEDICINE. 2023;12(16):5377
Intracardiac Thrombi in Morbus Adamantiades-Behcet in Two Swedish Patients
Da Mutten R; Borg A; Chatzidionysiou K; Parodis I
Article: DIAGNOSIS. 2023;10(3):218-224
Developing a European longitudinal and interprofessional curriculum for clinical reasoning
Hege I; Adler M; Donath D; Durning SJ; Edelbring S; Elven M; Bogusz A; Georg C; Huwendiek S; Koerner M; Kononowicz AA; Parodis I; Sodergren U; Wagner FL; Edstrom DW
Journal article: EUROPEAN MEDICAL JOURNAL RHEUMATOLOGY. 2023;10(1):33-44
Predictors of Renal Flares in Systemic Lupus Erythematosus
Gómez Á; Jägerback S; Parodis I
Article: RHEUMATOLOGY. 2023;62(7):2453-2463
Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study
Naveen R; Nikiphorou E; Joshi M; Sen P; Lindblom J; Agarwal V; Lilleker JB; Tan AL; Salim B; Ziade N; Velikova T; Gracia-Ramos AE; Kuwana M; Day J; Makol A; Distler O; Chinoy H; Traboco LS; Wibowo SAK; Tehozol EAZ; Serrano JR; Garcia-De La Torre I; Aggarwal R; Gupta L; Agarwal V; Parodis I
Article: RHEUMATOLOGY. 2023;62(7):2366-2376
COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety and tolerance in rheumatoid arthritis
Naveen R; Parodis I; Joshi M; Sen P; Lindblom J; Agarwal V; Lilleker JB; Tan AL; Nune A; Shinjo SK; Salim B; Ziade N; Velikova T; Edgar Gracia-Ramos A; Saavedra MA; Day J; Makol A; Distler O; Chinoy H; Agarwal V; Aggarwal R; Gupta L; Nikiphorou E
Article: RHEUMATOLOGY INTERNATIONAL. 2023;43(7):1265-1275
Systemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey
Naveen R; Thakare D; Kuwana M; Pauling J; Day J; Joshi M; Parodis I; Sen P; Jagtap K; Nikiphorou E; Saha S; Agarwal V; Chatterjee T; Lilleker J; Kardes S; Milchert M; Gheita T; Salim B; Velikova T; Gracia-Ramos AE; Tan AL; Nune A; Cavagna L; Saavedra M; Shinjo SK; Ziade N; Knitza J; Distler O; Chinoy H; Aggarwal R; Gupta L; Agarwal V; Makol A
Journal article: RHEUMATOLOGY. 2023;62(Supplement_2)
P065 Post COVID-19 Syndrome in patients with autoimmune rheumatic diseases: Results from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study
Gupta L; Sen P; Naveen R; Joshi M; Saha S; Jagtap K; Agarwal V; Distler O; Nikiphorou E; Tan AL; Shinjo SK; Ziade N; Milchert M; Parodis I; Kuwana M; Makol A; Pauling JD; Wincup C; Lilleker J; Nune A; Day J; Chinoy H; Agarwal V; Aggarwal R
Journal article: RHEUMATOLOGY. 2023;62(Supplement_2)
OA29 Flares following COVID-19 vaccination in patients with idiopathic inflammatory myopathies: combined analysis from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) studies
Gupta L; Naveen R; Griger Z; Agarwal V; Sen P; Joshi M; Saha S; Jagtap K; Distler O; Nikiphorou E; Tan AL; Shinjo SK; Ziade N; Milchert M; Parodis I; Kuwana M; Makol A; Pauling J; Wincup C; Lilleker J; Nune A; Day J; Chinoy H; Agarwal V; Aggarwal R
Article: JOURNAL OF AUTOIMMUNITY. 2023;136:103025
Distinct gene dysregulation patterns herald precision medicine potentiality in systemic lupus erythematosus
Lindblom J; Toro-Dominguez D; Carnero-Montoro E; Beretta L; Borghi MO; Castillo J; Enman Y; Mohan C; Alarcon-Riquelme ME; Barturen G; Parodis I
Article: INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES. 2023;26(4):727-739
Pain in individuals with idiopathic inflammatory myopathies, other systemic autoimmune rheumatic diseases, and without rheumatic diseases: A report from the COVAD study
Shinjo SK; Kim M; Hoff LS; Misse RG; Sen P; Naveen R; Day J; Cordeiro RA; Goncalves Junior J; Chatterjee TB; Lilleker JB; Agarwal V; Kardes S; Milchert M; Gheita T; Salim B; Velikova T; Gracia-Ramos AE; Parodis I; O'Callaghan AS; Nikiphorou E; Makol A; Tan AL; Cavagna LA; Saavedra MA; Ziade N; Knitza J; Kuwana M; Nune A; Distler O; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Article: AUTOIMMUNITY REVIEWS. 2023;22(4):103292
COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus
Giannopoulou N; Gupta L; Andreoli L; Lini D; Nikiphorou E; Aggarwal R; Agarwal V; Parodis I
Article: RHEUMATOLOGY. 2023;62(3):1204-1215
Impaired physical function in patients with idiopathic inflammatory myopathies: results from the multicentre COVAD patient-reported e-survey
Yoshida A; Kim M; Kuwana M; Ravichandran N; Makol A; Sen P; Lilleker JB; Agarwal V; Kardes S; Day J; Milchert M; Joshi M; Gheita T; Salim B; Velikova T; Edgar Gracia-Ramos A; Parodis I; Selva O'Callaghan A; Nikiphorou E; Chatterjee T; Tan AL; Nune A; Cavagna L; Saavedra MA; Shinjo SK; Ziade N; Knitza J; Distler O; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Article: FRONTIERS IN MEDICINE. 2023;10:1247354
Obesity is associated with pain and impaired mobility despite therapy in systemic lupus erythematosus
Borg A; Lindblom J; Gomez A; Soltani A; Enman Y; Heintz E; Regardt M; Grannas D; Emamikia S; Parodis I
Article: RHEUMATOLOGY INTERNATIONAL. 2023;43(1):47-58
COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey
Hoff LS; Ravichandran N; Shinjo SK; Day J; Sen P; Junior JG; Lilleker JB; Joshi M; Agarwal V; Kardes S; Kim M; Milchert M; Makol A; Gheita T; Salim B; Velikova T; Gracia-Ramos AE; Parodis I; O'Callaghan AS; Nikiphorou E; Tan AL; Chatterjee T; Cavagna L; Saavedra MA; Ziade N; Knitza J; Kuwana M; Nune A; Distler O; Cansu DU; Traboco L; Wibowo SAK; Tehozol EAZ; Serrano JR; Garcia-De La Torre I; Wincup C; Pauling JD; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Article: FRONTIERS IN IMMUNOLOGY. 2023;14:1257085
Serum profiling identifies CCL8, CXCL13, and IL-1RA as markers of active disease in patients with systemic lupus erythematosus
Lindblom J; Beretta L; Borghi MO; Alarcon-Riquelme ME; Parodis I
Article: RHEUMATOLOGY. 2022;62(1):65-76
COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study
Sen P; Ravichandran N; Nune A; Lilleker JB; Agarwal V; Kardes S; Kim M; Day J; Milchert M; Gheita T; Salim B; Velikova T; Gracia-Ramos AE; Parodis I; O'Callaghan AS; Nikiphorou E; Chatterjee T; Tan AL; Cavagna L; Saavedra MA; Shinjo SK; Ziade N; Knitza J; Kuwana M; Distler O; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Journal article: INDIAN JOURNAL OF ENDOCRINOLOGY AND METABOLISM. 2022;26(Suppl 8):s71
Abstract 167
Chatterjee T; Naveen R; Gracia-Ramos AE; Barman B; Sen P; Joshi M; Saha S; Nune A; Pande A; Velikova T; Parodis I; Tan AL; Shinjo SK; Boro H; Agarwal V; Aggarwal R; Gupta L
Article: RHEUMATOLOGY INTERNATIONAL. 2022;42(12):2151-2158
COVAD survey 2 long-term outcomes: unmet need and protocol
Fazal ZZ; Sen P; Joshi M; Ravichandran N; Lilleker JB; Agarwal V; Kardes S; Kim M; Day J; Makol A; Milchert M; Gheita T; Salim B; Velikova T; Gracia-Ramos AE; Parodis I; Nikiphorou E; Tan AL; Chatterjee T; Cavagna L; Saavedra MA; Shinjo SK; Ziade N; Selva-O'Callaghan A; Nune A; Knitza J; Kuwana M; Toro Gutierrez C-E; Vinicio Caballero-Uribe C; Dey D; Distler O; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Article: RHEUMATOLOGY. 2022;61(12):4752-4762
Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus
Emamikia S; Oon S; Gomez A; Lindblom J; Borg A; Enman Y; Morand E; Grannas D; van Vollenhoven RF; Nikpour M; Parodis I
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;23(22):13941
B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab
Parodis I; Gomez A; Lindblom J; Chow JW; Sjowall C; Sciascia S; Gatto M
Article: AUTOIMMUNITY REVIEWS. 2022;21(11):103188
Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature
Gomez A; Parodis I
Article: MUSCLE & NERVE. 2022;66(4):426-437
COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies
Gil-Vila A; Ravichandran N; Selva-O'Callaghan A; Sen P; Nune A; Gaur PS; Gonzalez RA; Lilleker JB; Joshi M; Agarwal V; Kardes S; Kim M; Day J; Makol A; Milchert M; Gheita T; Salim B; Velikova T; Gracia-Ramos AE; Parodis I; Nikiphorou E; Tan AL; Chatterjee T; Cavagna L; Saavedra MA; Shinjo SK; Ziade N; Knitza J; Kuwana M; Distler O; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Article: JOURNAL OF CLINICAL MEDICINE. 2022;11(17):5207
Low Serum BAFF Concentration Is Associated with Response to TNF Inhibitors in Seropositive Patients with Rheumatoid Arthritis
Hernandez-Breijo B; Parodis I; Novella-Navarro M; Martinez-Feito A; Navarro-Compan V; Diaz-Almiron M; Pascual-Salcedo D; Balsa A; Plasencia-Rodriguez C
Article: JOURNAL OF CLINICAL MEDICINE. 2022;11(7):1857
How Can We Enhance Adherence to Medications in Patients with Systemic Lupus Erythematosus? Results from a Qualitative Study
Emamikia S; Gentline C; Enman Y; Parodis I
Article: BRAIN SCIENCES. 2022;12(2):192
Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: A Systematic Literature Review of the Last Decade
Lindblom J; Mohan C; Parodis I
Article: JOURNAL OF CLINICAL INVESTIGATION. 2022;132(1):e147334
The CD6/ALCAM pathway promotes lupus nephritis via T cell-mediated responses
Chalmers SA; Ramachandran RA; Garcia SJ; Der E; Herlitz L; Ampudia J; Chu D; Jordan N; Zhang T; Parodis I; Gunnarsson I; Ding H; Shen N; Petri M; Mok CC; Saxena R; Polu KR; Connelly S; Ng CT; Mohan C; Putterman C
Article: FRONTIERS IN MEDICINE. 2022;9:1092325
EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus
Lindblom J; Zetterberg S; Emamikia S; Borg A; von Perner G; Enman Y; Heintz E; Regardt M; Grannas D; Gomez A; Parodis I
Article: FRONTIERS IN MEDICINE. 2022;9:852162
Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus
Parodis I; Gomez A; Lindblom J; Chow JW; Doria A; Gatto M
Journal article: INDIAN JOURNAL OF RHEUMATOLOGY. 2022;17(2):188-191
Vaccine hesitancy in patients with autoimmune diseases: Data from the coronavirus disease-2019 vaccination in autoimmune diseases study
Sen P; Lilleker JB; Agarwal V; Kardes S; Milchert M; Gheita T; Salim B; Velikova T; Gracia-Ramos AE; Parodis I; O'Callaghan AS; Nikiphorou E; Tan AL; Cavagna L; Saavedra MA; Shinjo SK; Ziade N; Knitza J; Kuwana M; Cagnotto G; Nune A; Distler O; Chinoy H; Aggarwal R; Gupta L
Article: RHEUMATOLOGY INTERNATIONAL. 2022;42(1):23-29
COVID-19 vaccination in autoimmune disease (COVAD) survey protocol
Sen P; Gupta L; Lilleker JB; Aggarwal V; Kardes S; Milchert M; Gheita T; Salim B; Velikova T; Gracia-Ramos AE; Parodis I; O'Callaghan AS; Nikiphorou E; Tan AL; Cavagna L; Saavedra MA; Shinjo SK; Ziade N; Knitza J; Kuwana M; Cagnotto G; Nune A; Distler O; Chinoy H; Aggarwal V; Aggarwal R
Article: FRONTIERS IN IMMUNOLOGY. 2022;13:796508
Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab
Parodis I; Gomez A; Chow JW; Borg A; Lindblom J; Gatto M
Article: INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 2021;18(21):11202
Clinical Reasoning Needs to Be Explicitly Addressed in Health Professions Curricula: Recommendations from a European Consortium
Parodis I; Andersson L; Durning SJ; Hege I; Knez J; Kononowicz AA; Lidskog M; Petreski T; Szopa M; Edelbring S
Article: RHEUMATOLOGY. 2021;60(10):4703-4716
EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus
Lindblom J; Gomez A; Borg A; Emamikia S; Ladakis D; Matilla J; Pehr M; Cobar F; Enman Y; Heintz E; Regardt M; Parodis I
Article: RHEUMATOLOGY. 2021;60(9):4205-4217
Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE
Borg A; Gomez A; Cederlund A; Cobar F; Qiu V; Lindblom J; Emamikia S; Enman Y; Pettersson S; Parodis I
Article: RHEUMATOLOGY. 2021;60(9):4348-4354
De novo lupus nephritis during treatment with belimumab
Parodis I; Vital EM; Hassan S-U; Jonsen A; Bengtsson AA; Eriksson P; Leonard D; Gunnarsson I; Ronnblom L; Sjowall C
Article: LUPUS SCIENCE & MEDICINE. 2021;8(1):e000515
Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case-control study
Samuelsson I; Parodis I; Gunnarsson I; Zickert A; Hofman-Bang C; Wallen H; Svenungsson E
Article: SCIENTIFIC REPORTS. 2021;11(1):11632
BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors
Hernandez-Breijo B; Navarro-Compan V; Plasencia-Rodriguez C; Parodis I; Gehin JE; Martinez-Feito A; Novella-Navarro M; Mezcua A; Warren DJ; Nozal P; Pascual-Salcedo D; Balsa A
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2021;80:260-261
POS0101 ADVERSE HEALTH-RELATED QUALITY OF LIFE OUTCOME DESPITE ADEQUATE CLINICAL RESPONSE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS
Gomez A; Lindblom J; Qiu V; Cederlund A; Borg A; Emamikia S; Enman Y; Lampa J; Parodis I
Article: RHEUMATOLOGY. 2021;60(3):1260-1272
Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus
Gomez A; Butrus FH; Johansson P; Akerstrom E; Soukka S; Emamikia S; Enman Y; Pettersson S; Parodis I
Article: FRONTIERS IN MEDICINE. 2021;8:651249
Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus
Gomez A; Qiu V; Cederlund A; Borg A; Lindblom J; Emamikia S; Enman Y; Lampa J; Parodis I
Article: RHEUMATOLOGY. 2020;59(11):3424-3434
Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis
Parodis I; Adamichou C; Aydin S; Gomez A; Demoulin N; Weinmann-Menke J; Houssiau FA; Tamirou F
Article: RHEUMATOLOGY. 2020;59(9):2237-2249
ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus
Parodis I; Gokaraju S; Zickert A; Vanarsa K; Zhang T; Habazi D; Botto J; Alves CS; Giannopoulos P; Larsson A; Svenungsson E; Gunnarsson I; Mohan C
Article: JOURNAL OF CLINICAL MEDICINE. 2020;9(6):E1813-1813
Use of Antimalarial Agents Is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus
Gomez A; Soukka S; Johansson P; Akerstrom E; Emamikia S; Enman Y; Chatzidionysiou K; Parodis I
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2020;21(10):E3463-3463
Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
Parodis I; Akerstrom E; Sjowall C; Sohrabian A; Jonsen A; Gomez A; Frodlund M; Zickert A; Bengtsson AA; Roennelid J; Gunnarsson I
Article: NATURE REVIEWS DISEASE PRIMERS. 2020;6(1):7
Lupus nephritis
Anders H-J; Saxena R; Zhao M-H; Parodis I; Salmon JE; Mohan C
Article: RHEUMATOLOGY. 2019;58(12):2170-2176
Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus
Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K
Article: ARTHRITIS RESEARCH & THERAPY. 2019;21(1):259
Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus
Sohrabian A; Parodis I; Carlstromer-Berthen N; Frodlund M; Jonsen A; Zickert A; Sjowall C; Bengtsson AA; Gunnarsson I; Ronnelid J
Article: LANCET RHEUMATOLOGY. 2019;1(3):E163-E173
Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials
Parodis I; Emamikia S; Gomez A; Gentline C; Arkema EV; Chatzidionysiou K; van Vollenhoven RF
Article: ARTHRITIS CARE & RESEARCH. 2019;71(6):811-821
The Impact of Belimumab and Rituximab on Health-Related Quality of Life in Patients With SystemicLupus Erythematosus
Parodis I; Benavides AHL; Zickert A; Pettersson S; Moller S; Henriksson EW; Voss A; Gunnarsson I
Article: EBIOMEDICINE. 2019;40:517-527
B cell alterations during BAFF inhibition with belimumab in SLE
Ramskold D; Parodis I; Lakshmikanth T; Sippl N; Khademi M; Chen Y; Zickert A; Mikes J; Achour A; Amara K; Piehl F; Brodin P; Gunnarsson I; Malmstrom V
Article: EXPERT OPINION ON BIOLOGICAL THERAPY. 2019;19(2):157-168
Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies
Parodis I; Emamikia S; Gomez A; Gunnarsson I; van Vollenhoven RF; Chatzidionysiou K
Article: PLOS ONE. 2019;14(2):e0212068
Serum Axl predicts histology-based response to induction therapy and long-term renal outcome in lupus nephritis
Parodis I; Ding H; Zickert A; Cosson G; Fathima M; Gronwall C; Mohan C; Gunnarsson I
Article: EXPERT OPINION ON BIOLOGICAL THERAPY. 2018;18(8):911-920
Smoking reduces the efficacy of belimumab in mucocutaneous lupus
Parodis I; Gomez A; Frodlund M; Jonsen A; Zickert A; Sjowall C; Bengtsson AA; Gunnarsson I
Article: LUPUS. 2018;27(9):1470-1478
Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL
Parodis I; Soder F; Faustini F; Kasza Z; Samuelsson I; Zickert A; Svenungsson E; van Vollenhoven RF; Malmstrom V; Wermeling F; Gunnarsson I
Journal article: JOURNAL OF IMMUNOLOGY. 2018;200(1_Supplement):175.17
ALCAM and VCAM-1 as potential urinary biomarkers in Caucasian lupus patients
Habazi D; Vanarsa K; Stanley S; Gokaraju S; Ding H; Parodis I; Gunnarsson I; Mohan C
Article: JMIR MEDICAL EDUCATION. 2018;4(1):e4
Increasing Reasoning Awareness: Video Analysis of Students' Two-Party Virtual Patient Interactions.
Edelbring S; Parodis I; Lundberg IE
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2017;46(4):263-272
Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis
Parodis I; Ding H; Zickert A; Arnaud L; Larsson A; Svenungsson E; Mohan C; Gunnarsson I
Article: LUPUS SCIENCE & MEDICINE. 2016;3(1):e000170
Interferon (IFN)-λ is a potential mediator in lupus nephritis
Zickert A; Oke V; Parodis L; Svenungsson E; Sundstrom Y; Gunnarsson I
Article: PLOS ONE. 2016;11(6):e0158076
Antiphospholipid Antibodies in Lupus Nephritis
Parodis I; Arnaud L; Gerhardsson J; Zickert A; Sundelin B; Malmstrom V; Svenungsson E; Gunnarsson I
Article: LUPUS SCIENCE & MEDICINE. 2015;2(1):e000061
Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy
Parodis I; Zickert A; Sundelin B; Axelsson M; Gerhardsson J; Svenungsson E; Malmstrom V; Gunnarsson I
Article: BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY. 2013;27(3):341-349
Biologics in SLE: Towards new approaches
van Vollenhoven RF; Parodis I; Levitsky A
Article: LUPUS. 2013;22(4):372-380
Belimumab for systemic lupus erythematosus: a practice-based view
Parodis I; Axelsson M; Gunnarsson I
Show more

All other publications

Editorial comment: ARP RHEUMATOLOGY. 2024;3(2):81-82
Lessons learnt from the recent recommendations for the non-pharmacological management of systemic sclerosis
Santiago T; Fernandes R; Ferreira R; Parodis I; Bostrom C
Review: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2024;35(2):328
Evolving Concepts in Treat-to-Target Strategies for Systemic Lupus Erythematosus
Nikolopoulos D; Lourenco MH; Depascale R; Triantafyllias K; Parodis I
Review: RHEUMATOLOGY INTERNATIONAL. 2024;44(5):765-778
Efficacy of lifestyle interventions in the management of systemic lupus erythematosus: a systematic review of the literature
Tsoi A; Gomez A; Bostroem C; Pezzella D; Chow JW; Girard-Guyonvarc'h C; Stamm T; Arnaud L; Parodis I
Review: EXPERT OPINION ON PHARMACOTHERAPY. 2024;25(6):705-716
Advances in the pharmacological management of systemic lupus erythematosus
Tsoi A; Nikolopoulos D; Parodis I
Letter: LUPUS SCIENCE & MEDICINE. 2024;11(1):e001215
Enhancing lupus outcomes by means of biology beyond overt clinical features, exemplified in an in-depth investigation of the effects of circadian rhythm disruption
Parodis I
Review: RHEUMATOLOGY ADVANCES IN PRACTICE. 2024;8(2):rkae037
Lifestyle interventions in the management of systemic sclerosis: a systematic review of the literature
Parodis I; Tsoi A; Gomez A; Chow JW; Girard-Guyonvarc'h C; Stamm T; Bostrom C
Conference publication: COMPANION OF THE 2024 ACM/IEEE INTERNATIONAL CONFERENCE ON HUMAN-ROBOT INTERACTION, HRI 2024 COMPANION. 2024;:273-277
Creating Virtual Patients using Robots and Large Language Models: A Preliminary Study with Medical Students
Borg A; Parodis I; Skantze G
Conference publication: 2024;:a59.1-a5a59
P23 Presence of anti-Sm autoantibodies is associated with abatement of attainability of LLDAS and DORIS remission in systemic lupus erythematosus
Lourenço MH; Cetrez N; Tsoi A; Lindblom J; Nikolopoulos D; Parodis I
Conference publication: 2024;:a58.2-a5a58
P22 Consistent benefits from belimumab irrespective of antiphospholipid autoantibody profile, yet not in the presence of lupus anticoagulant
Tsoi A; Lindblom J; Cetrez N; Parodis I
Conference publication: 2024;:a39-a40
O42 Patients with systemic lupus erythematosus experience poor health-related quality of life despite a low disease activity state or remission
Parodis I; Lindblom J; Cetrez N; Palazzo L; Ala H; Nikpour M; Levitsky A; Strand V
Conference publication: 2024;:a28.2-a2a29
O28 Unveiling the impact of neuropsychiatric involvement in systemic lupus erythematosus on damage accrual
Nikolopoulos D; Cetrez N; Lindblom J; Parodis I
Conference publication: 2024;:a14-a15
O11 Unsupervised machine-learning identifies distinct clusters based on B cell phenotyping and autoantibody profiles in patients with systemic lupus erythematosus
Gatto M; Depascale R; Cetrez N; Lindblom J; Nikolopoulos D; Doria A; Parodis I
Conference publication: 2024;:a119.1-a1a119
P110 Impact of neuropsychiatric involvement on health-related quality of life in patients with systemic lupus erythematosus
Nikolopoulos D; Cetrez N; Lindblom J; Parodis I
Conference publication: 2024;:a86.1-a8a86
P62 Machine learning approaches for prediction of renal flares in systemic lupus erythematosus: knowledge-driven models outperformed data-driven models
Cetrez N; Lindblom J; Mutten RD; Nikolopoulos D; Parodis I
Conference publication: 2024;:a85.2-a8a86
P61 Harnessing machine learning to predict neuropsychiatric events in systemic lupus erythematosus
Cetrez N; Lindblom J; Mutten RD; Nikolopoulos D; Parodis I
Conference publication: 2024;:a21
O20 Lupus low disease activity state and organ damage in relation to quality of life in SLE: a cohort study with up to 11 years of follow-up
Parodis I; Stephens T; Dominicus A; Eek D; Sjöwall C
Conference publication: 2024;:a140-a141
P134 Factors associated with discordance between patient and physician perception of disease activity among patients with systemic lupus erythematosus: an international collaborative study
Ghosh S; Narayanan RS; Bechman K; Parodis I; Kadam E; Katchamart W; Goo PA; Gracia-Ramos AE; Sen P; Nikiphorou E; Saha S; Tan AL; Velikova T; Milchert M; Knitza J; Caballero C; Dzifa D; Chinoy H; Aggarwal R; Agarwal V; Gupta L; Wincup C
Conference publication: 2024;:a161.1-a1a161
P156 Recommendations of nonpharmacological management of SLE and SSc: Assessing alignment with clinical care
Marchiori F; Schriemer R; Ende EVD; Kocher A; Ritschl V; Barten B; Galetti I; Westhovens R; Distler O; Bostrom C; Parodis I
Conference publication: 2024;:a24-a25
O23 Interferon upregulation and B and plasma cell gene dysregulation patterns reveal three distinct lupus nephritis subgroups with differential anticipated response to targeted therapies
Parodis I; Lindblom J; Toro-Domínguez D; Beretta L; Borghi MO; Castillo J; Carnero-Montoro E; Enman Y; Mohan C; Alarcón-Riquelme ME; Barturen G; Nikolopoulos D
Conference publication: 2024;:a17-a18
O15 B cell, T cell, cytotoxic/NK cell, and mitochondrial gene dysregulation patterns separate neuropsychiatric systemic lupus erythematosus patients into two distinct subgroups with differential anticipated response to targeted therapies
Lindblom J; Nikolopoulos D; Toro-Domínguez D; Carnero-Montoro E; Borghi MO; Castillo J; Iacobaeus E; Enman Y; Mohan C; Beretta L; Alarcón-Riquelme ME; Barturen G; Parodis I
Conference publication: 2024;:a36.2-a3a37
O39 Immune deposit resorption in per-protocol repeat kidney biopsy performed in patients with proliferative lupus nephritis
Cetrez N; Tamirou F; Nieuwland S; Aydin S; Parodis I; Houssiau FA
Review: LUPUS SCIENCE & MEDICINE. 2024;11(1):e001114
Clinical trial outcomes for SLE: what we have and what we need
Arnaud L; Parodis I; Devilliers H; Chasset F
Letter: INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES. 2024;27(1):e14961
Flares of autoimmune rheumatic disease following COVID-19 infection: Observations from the COVAD study
Sandhu NK; Ravichandraan N; Nune A; Day J; Sen P; Nikiphorou E; Tan AL; Joshi M; Saha S; Shinjo SK; Jagtap K; Agarwal V; Ziade N; Velikova T; Milchert M; Parodis I; Gracia-Ramos AE; Cavagna L; Kuwana M; Knitza J; Makol A; Patel A; Pauling JD; Wincup C; Barman B; Tehozol EAZ; Serrano JR; Torre IG-DL; Colunga-Pedraza IJ; Merayo-Chalico J; Okwara CC; Katchamart W; Goo PA; Shumnalieva R; Chen Y-M; Hoff LS; Kibbi LE; Halabi H; Vaidya B; Shaharir SS; Hasan ATMT; Dey D; Gutierrez CET; Caballero-Uribe CV; Lilleker JB; Salim B; Gheita T; Saavedra MA; Chatterjee T; Distler O; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Review: PATIENT RELATED OUTCOME MEASURES. 2023;14:1-13
Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence
Gomez A; Enman Y; Parodis I
Editorial comment: JOURNAL OF RHEUMATOLOGY. 2023;51(1):4-6
More Evidence on the Validity of the Measurement Properties of PROMIS Computerized Adaptive Tests in Systemic Lupus Erythematosus
Touma Z; Parodis I; Strand V
Corrigendum: JOURNAL OF AUTOIMMUNITY. 2023;140:103052
Distinct gene dysregulation patterns herald precision medicine potentiality in systemic lupus erythematosus (vol 136, 103025, 2023)
Lindblom J; Toro-Dominguez D; Carnero-Montoro E; Beretta L; Borghi MO; Castillo J; Enman Y; Mohan C; Alarcon-Riquelme ME; Barturen G; Parodis I
Review: JOURNAL OF CLINICAL MEDICINE. 2023;12(19):6268
B Cell Tolerance and Targeted Therapies in SLE
Parodis I; Long X; Karlsson MCI; Huang X
Review: RMD OPEN. 2023;9(3):e003297
Systematic literature review informing the EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis
Parodis I; Gomez A; Tsoi A; Chow JW; Pezzella D; Girard C; Stamm TA; Bostrom C
Conference publication: 2023;:a51.1-a5a51
LSO-028 Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab
Parodis I; Lindblom J; Çetrez N; Palazzo L; Ala H; Houssiau F; Sjöwall C; Rovin B
Conference publication: 2023;:a149.1-a1a149
LP-170 Predictors of neuropsychiatric flares In Patients With Systemic Lupus Erythematosus: Results From Five Phase III clinical trials of belimumab
Palazzo L; Lindblom J; Cetrez N; Ala H; Parodis I
Conference publication: 2023;:a52.1-a5a52
LSO-030 Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab
Gomez A; Jägerback S; Parodis I
Conference publication: 2023;:a22.2-a2a23
LO-027 COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus
Giannopoulou N; Gupta L; Andreoli L; Lini D; Nikiphorou E; Aggarwal R; Agarwal V; Parodis I
Conference publication: 2023;:a16.2-a1a17
LO-019 Breakthrough SARS-CoV-2 infection in fully vaccinated patients with systemic lupus erythematosus: results from the COVID-19 vaccination in autoimmune disease (COVAD) study
Olsson EK; Naveen R; Nikiphorou E; Lindblom J; Saha S; Shaharir SS; Katchamart W; Goo PA; Traboco L; Chen Y-M; Jagtap K; Lilleker J; Nune A; Pauling J; Wincup C; Agarwal V; Dzifa D; Toro Gutierrez CE; Caballero CV; Chinoy H; Agarwal V; Aggarwal R; Gupta L; Parodis I
Conference publication: 2023;:a75
LSO-065 Belimumab in combination with antimalarial agents prevent renal flares in patients with systemic lupus erythematosus and moderate-to-high extra-renal activity: results from four randomised clinical trials
Gomez A; Jägerback S; Sjöwall C; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:1088
PREDICTORS OF NEUROPSYCHIATRIC FLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB
Palazzo L; Lindblom J; Cetrez N; Ala H; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:909-910
PREDICTORS OF DE NOVO RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS - TIME TO REVISIT BELIMUMAB DOSE FOR EXTRA-RENAL DISEASE? RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB
Parodis I; Lindblom J; Cetrez N; Palazzo L; Ala H; Houssiau F; Sjowall C; Rovin BH
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:1495-1496
COVID-19 VACCINE SAFETY DURING PREGNANCY IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Giannopoulou N; Gupta L; Andreoli L; Lini D; Nikiphorou E; Aggarwal R; Agarwal V; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:1467.3-141468
LOW-DOSE BELIMUMAB AND ANTIMALARIAL AGENTS PREVENT RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM FOUR RANDOMISED CLINICAL TRIALS
Gomez A; Jagerback S; Sjowall C; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:34
PREDICTORS OF RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS: A POST-HOC ANALYSIS OF FOUR PHASE III CLINICAL TRIALS OF BELIMUMAB
Jagerback S; Gomez A; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:540-541
BREAKTHROUGH SARS-COV-2 INFECTION IN FULLY VACCINATED PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASE (COVAD) STUDY
Olsson EK; Ravichandran N; Nikiphorou E; Lindblom J; Saha S; Shaharir SS; Katchamart W; Goo PA; Traboco L; Chen YM; Jagtap K; Lilleker JB; Nune A; Pauling J; Wincup C; Agarwal V; Dzifa D; Toro Gutierrez CE; Vinicio Caballero C; Chinoy H; Agarwal V; Aggarwal R; Gupta L; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:56.1-5656
PREVALENCE, CHARACTERISTICS, AND PREDICTORS OF BREAKTHROUGH COVID-19 INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASE (COVAD) STUDY
Ravichandran N; Parodis I; Gupta L; Katsuyuki Shinjo S; Ziade N; Milchert M; Cavagna L; Tan AL; Lilleker JB; Nune A; Pauling J; Wincup C; Katchamart W; Goo PA; Study C; Chinoy H; Aggarwal R; Agarwal V; Nikiphorou E
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:902-903
FACTORS ASSOCIATED WITH SURVIVAL AND DISCONTINUATION OF ANTIMALARIAL AGENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A SWEDISH LONGITUDINAL REGISTRY
Walhelm T; Wirestam L; Enman Y; Parodis I; Sjowall C
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:1456-1458
EVALUATING GLOBAL PATTERNS IN TREATMENT AND PREVALENCE OF COMORBIDITIES IN SYSTEMIC LUPUS ERYTHEMATOSUS
Holloway A; Lee SY; Nikiphorou E; Parodis I; Ravichandran N; Day J; Joshi M; Saha S; Shaharir SS; Katchamart W; Goo PA; Traboco L; Chen YM; Sen P; Lilleker JB; Nune A; Pauling J; Tan AL; Ziade N; Milchert M; Gracia-Ramos AE; Vinicio Caballero C; Agarwal V; Aggarwal R; Gupta L; Wincup C
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:375-376
POST COVID-19 SYNDROME IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES: RESULTS FROM THE COVAD STUDY
Sen P; Ravichandran N; Joshi M; Saha S; Jagtap K; Agarwal V; Distler O; Nikiphorou E; Tan AL; Shinjo SK; Ziade N; Velikova T; Milchert M; Parodis I; Gracia-Ramos AE; Cavagna L; Kuwana M; Knitza J; Makol A; Patel A; Pauling J; Wincup C; Barman B; Zamora-Tehozol EA; Rojas-Serrano J; Garcia-De La Torre I; Colunga-Pedraza IJ; Merayo-Chalico J; Katchamart W; Goo PA; Chen YM; Hoff LS; Kibbi L; Halabi H; Vaidya B; Shaharir SS; Shumnalieva R; Hasan ATMT; Dzifa D; Toro Gutierrez CE; Vinicio Caballero C; Lilleker JB; Salim B; Gheita TA; Chatterjee T; Nune A; Saavedra MA; Day J; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:56-57
COVID-19 VACCINE SAFETY DURING PREGNANCY AND BREASTFEEDING IN WOMEN WITH AUTOIMMUNE DISEASES: RESULTS FROM THE COVAD STUDY
Andreoli L; Lini D; Schreiber K; Sen P; Ravichandran N; Parodis I; Toro Gutierrez CE; Katchamart W; Goo PA; Shumnalieva R; Chibuzo OC; Velikova T; Day J; Joshi M; Katsuyuki Shinjo S; Gracia-Ramos AE; Cavagna L; Kuwana M; Knitza J; Makol A; Chen YM; Study C; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:952-953
IMPAIRED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: A CROSS-SECTIONAL ANALYSIS FROM AN INTERNATIONAL SURVEY
Yoshida A; Li Y; Maroufy V; Kuwana M; Ravichandran N; Makol A; Sen P; Lilleker JB; Agarwal V; Kardes S; Day J; Milchert M; Joshi M; Gheita TA; Salim B; Velikova T; Gracia-Ramos AE; Parodis I; Nikiphorou E; Tan AL; Nune A; Cavagna L; Saavedra MA; Katsuyuki Shinjo S; Ziade N; Knitza J; Distler O; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:942-943
MULTIMORBIDITY AND PROMIS HEALTH OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: DATA FROM A LARGE, GLOBAL E-SURVEY (COVAD STUDY)
Fornaro M; Venerito V; Iannone F; Ravichandran N; Nikiphorou E; Joshi M; Tan AL; Saha S; Shinjo SK; Agarwal V; Ziade N; Velikova T; Jagtap K; Milchert M; Parodis I; Gracia-Ramos AE; Cavagna L; Kuwana M; Knitza J; Makol A; Dzifa D; Toro Gutierrez CE; Vinicio Caballero C; Distler O; Day J; Study C; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:555-556
COMORBIDITIES, COMPLEX MULTIMORBIDITY AND PROMIS HEALTH OUTCOMES AMONGAUTOIMMUNE RHEUMATIC DISEASES: DATA FROM THE COVAD STUDY
Gupta L; Ravichandran N; Venerito V; Dey M; Sen P; Saha S; Tan AL; Shinjo SK; Agarwal V; Joshi M; Ziade N; Velikova T; Jagtap K; Milchert M; Parodis I; Gracia-Ramos AE; Cavagna L; Kuwana M; Knitza J; Makol A; Dzifa D; Gutierrez CET; Caballero CV; Distler O; Day J; Chinoy H; Aggarwal R; Agarwal V; Nikiphorou E
Letter: RHEUMATOLOGY. 2023;62(5):e147-e152
Higher risk of short term COVID-19 vaccine adverse events in myositis patients with autoimmune comorbidities: results from the COVAD study
Dey M; Naveen R; Nikiphorou E; Sen P; Saha S; Lilleker JB; Agarwal V; Kardes S; Day J; Milchert M; Joshi M; Gheita T; Salim B; Velikova T; Edgar Gracia-Ramos A; Parodis I; Selva O'Callaghan A; Kim M; Chatterjee T; Tan AL; Makol A; Nune A; Cavagna L; Saavedra MA; Shinjo SK; Ziade N; Knitza J; Kuwana M; Distler O; Barman B; Singh YP; Ranjan R; Jain A; Pandya SC; Pilania RK; Sharma A; Manoj MM; Gupta V; Kavadichanda CG; Patro PS; Ajmani S; Phatak S; Goswami RP; Chowdhury AC; Mathew AJ; Shenoy P; Asranna A; Bommakanti KT; Shukla A; Pande AR; Chandwar K; Pauling JD; Wincup C; Cansu DU; Zamora Tehozol EA; Rojas Serrano J; Garcia-De La Torre I; Del Papa N; Sambataro G; Fabiola A; Govoni M; Parisi S; Bartoloni Bocci E; Sebastiani GD; Fusaro E; Sebastiani M; Quartuccio L; Franceschini F; Sainaghi PP; Orsolini G; De Angelis R; Danielli MG; Venerito V; Traboco LS; Hoff LS; Kusumo Wibowo SA; Tomaras S; Langguth D; Limaye V; Needham M; Srivastav N; Yoshida A; Nakashima R; Sato S; Kimura N; Kaneko Y; Loarce-Martos J; Prieto-Gonzalez S; Gil-Vila A; Aranega Gonzalez R; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Editorial comment: LANCET RHEUMATOLOGY. 2023;5(1):E4-E6
Molecular signature-based decision making in the era of targeted therapies for systemic lupus erythematosus
Parodis I
Review: FRONTIERS IN MEDICINE. 2023;10:1217147
Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition
Nikolopoulos D; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:1110-1112
IDENTIFYING DETERMINANTS OF FAVOURABLE AND POOR PHYSICAL FUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM AN INTERNATIONAL COLLABORATIVE STUDY
Lee SY; Holloway A; Nikiphorou E; Parodis I; Ravichandran N; Day J; Joshi M; Saha S; Jagtap K; Katchamart W; Goo PA; Vaidya B; Velikova T; Sen P; Katsuyuki Shinjo S; Agarwal V; Tan AL; Ziade N; Milchert M; Gracia-Ramos AE; Vinicio Caballero C; Chinoy H; Agarwal V; Aggarwal R; Gupta L; Wincup C
Conference publication: RHEUMATOLOGY. 2023;62
POST COVID-19 SYNDROME IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY
Gupta L; Sen P; Naveen R; Joshi M; Saha S; Jagtap K; Agarwal V; Distler O; Nikiphorou E; Tan AL; Shinjo SK; Ziade N; Milchert M; Parodis I; Kuwana M; Makol A; Pauling JD; Wincup C; Lilleker J; Nune A; Day J; Chinoy H; Agarwal V; Aggarwal R
Conference publication: RHEUMATOLOGY. 2023;62
FLARES FOLLOWING COVID-19 VACCINATION IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: COMBINED ANALYSIS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDIES
Gupta L; Naveen R; Griger Z; Agarwal V; Sen P; Joshi M; Saha S; Jagtap K; Distler O; Nikiphorou E; Tan AL; Shinjo SK; Ziade N; Milchert M; Parodis I; Kuwana M; Makol A; Pauling J; Wincup C; Lilleker J; Nune A; Day J; Chinoy H; Agarwal V; Aggarwal R
Conference publication: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2023;52:45
Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase Ill clinical trials of belimumab
Palazzo L; Lindblom J; Cetrez N; Ala H; Parodis I
Conference publication: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2023;52:46
De novo renal flares in SLE patients treated for active extra renal disease within five phase Ill clinical trials of belimumab. Implications for revisiting belimumab dose
Parodis I; Lindblom J; Cetrez N; Palazzo L; Ala H; Houssiau F; Sjowall C; Rovin B
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2023;75:241-244
COVID-19 Vaccination-related Delayed Adverse Events Among Patients with Systemic Lupus Erythematosus: Results from the COVAD Study
Fathima M; Doskaliuk B; Lindblom J; Nikiphorou E; Wincup C; Saha S; Shaharir SS; Katchamart W; Goo PA; Traboco L; Chen Y-M; Jagtap K; Lilleker J; Nune A; Pauling J; Agarwal V; Dzifa D; Toro Gutierrez CE; Vinicio Caballero C; Chinoy H; Aggarwal R; Agarwal V; Gupta L; Parodis I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2023;75:260-262
New-Onset Systemic Autoimmune Diseases Following COVID-19 Vaccination - Results from the COVAD Study
Shumnalieva R; Hannah J; Roy D; Naveen R; Javaid M; Gonzalez D; Joshi M; Gracia-Ramos AE; Cavagna L; Sen P; Day J; Saha S; Parodis I; Nikiphorou E; Kadam E; Knitza J; Aggarwal R; Agarwal V; Gupta L
Editorial comment: JOURNAL OF CLINICAL MEDICINE. 2022;11(22):6869
Clinical Heterogeneity, Unmet Needs and Long-Term Outcomes in Patients with Systemic Lupus Erythematosus
Sjowall C; Parodis I
Conference publication: 2022;:a35.2-a3a36
PO.2.27 Early changes in the circulating B cell compartment associated with response to treatment and occurrence of flares in patients receiving therapy for active systemic lupus erythematosus
Gatto M; Gomez Gonzales A; Lindblom J; Doria A; Parodis I
Conference publication: 2022;:a9-a10
S06.1 B cell kinetics upon therapy commencement for active extra-renal systemic lupus erythematosus in relation to development of renal flares
Parodis I; Gomez A; Lindblom J; Chow J; Sjöwall C; Sciascia S; Gatto M
Conference publication: 2022;:a109.2-a1a110
PO.7.147 Obesity and tobacco smoking are independently associated with poor patient-reported outcomes in patients with systemic lupus erythematosus from a Swedish tertiary referral centre
Gomez A; Parodis I; Sjöwall C
Conference publication: 2022;:a97-a98
PO.6.128 Factors associated with survival and discontinuation of antimalarial agents in systemic lupus erythematosus: results from a swedish longitudinal registry
Walhelm T; Wirestam L; Parodis I; Sjöwall C
Conference publication: 2022;:a91-a92
PO.6.119 Low-dose belimumab and antimalarial agents prevent renal flares in systemic lupus erythematosus: results from four randomised clinical trials
Gomez A; Jägerback S; Sjöwall C; Parodis I
Conference publication: 2022;:a82
PO.5.104 Evaluation of traditional laboratory markers as predictors of renal flares: a post-hoc analysis of four phase iii clinical trials of SLE
Jägerback S; Gomez A; Parodis I
Conference publication: 2022;:a73-a74
PO.4.92 Taxonomy, treatment, targets and remission in systemic lupus erythematosus: the 3TR-SLE study protocol
Parodis I; Voskuyl A; Alarcón-Riquelme M; Beretta L
Conference publication: 2022;:a92
PO.6.120 Non-pharmacological management of systemic lupus erythematosus and systemic sclerosis: a systematic literature review to inform eular recommendations
Parodis I; Gomez A; Tsoi A; Chow J; Pezzella D; Girard C; Stamm T; Boström C
Conference publication: 2022;:a33.1-a3a33
PO.1.21 Attainment of EQ-5D-3L full health state after therapy is associated with decelerated organ damage accrual in systemic lupus erythematosus
Lindblom J; Zetterberg S; Borg A; Emamikia S; Von Perner G; Enman Y; Heintz E; Regardt M; Grannas D; Gomez A; Parodis I
Conference publication: 2022;:a29.1-a2a29
PO.1.12 Transcriptome profiling and autoimmunity-related serological markers identify TP53 and C3aR as drug targets in neuropsychiatric systemic lupus erythematosus
Lindblom J; Toro-Domínguez D; Carnero-Montoro E; Borghi M; Castillo J; Iacobaeus E; Enman Y; Repsilber D; Mohan C; Alarcón-Riquelme M; Barturen G; Parodis I
Conference publication: 2022;:a110.2-a1a111
PO.7.149 Associations between abnormal bmi and patient-reported health-related quality of life before and after therapeutic intervention in patients with systemic lupus erythematosus
Borg A; Soltani A; Emamikia S; Lindblom J; Gomez A; Von Perner G; Enman Y; Heintz E; Regardt M; Grannas D; Parodis I
Conference publication: 2022;:a109.1-a1a109
PO.7.146 Sensitivity analysis of EQ-5D-3L index scores in relation to discriminative and known-groups validity in systemic lupus erythematosus
Hua N; Gomez A; Lindblom J; Von Perner G; Enman Y; Regardt M; Heintz E; Emamikia S; Grannas D; Parodis I
Conference publication: 2022;:a78.2-a7a78
PO.5.99 Drug repurposing for treating lupus nephritis based on transcriptome profiling and autoimmunity-related serological markers
Parodis I; Lindblom J; Toro-Domínguez D; Carnero-Montoro E; Borghi M; Castillo J; Enman Y; Repsilber D; Mohan C; Alarcón-Riquelme M; Barturen G
Conference publication: 2022;:a7-a8
S04.2 Medication adherence in patients with systemic lupus erythematosus: results from a Swedish survey
Emamikia S; Gomez Gonzalez A; Ådahl T; Von Perner G; Enman Y; Chatzidionysiou K; Arkema E; Parodis I
Review: JOURNAL OF CLINICAL MEDICINE. 2022;11(19):5759
Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature
Palazzo L; Lindblom J; Mohan C; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2022;81:439
CAN WE ENHANCE ADHERENCE TO MEDICATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS? RESULTS FROM A QUALITATIVE STUDY
Emamikia S; Gentline C; Enman Y; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2022;81:326
DRUG REPURPOSING FOR TREATING LUPUS NEPHRITIS BASED ON TRANSCRIPTOME PROFILING AND AUTOIMMUNITY-RELATED SEROLOGICAL MARKERS
Parodis I; Lindblom J; Toro-Dominguez D; Borghi MO; Enman Y; Repsilber D; Mohan C; Alarcon-Riquelme M; Barturen G
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2022;81:326
TRANSCRIPTOME PROFILING AND AUTOIMMUNITY-RELATED SEROLOGICAL MARKERS IDENTIFY TP53 AND C3AR AS DRUG TARGETS IN NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS
Lindblom J; Toro-Dominguez D; Borghi MO; Iacobaeus E; Enman Y; Repsilber D; Mohan C; Alarcon-Riquelme M; Barturen G; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2022;81:748
HIGH FATIGUE SCORES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: A MULTIGROUP COMPARATIVE STUDY FROM THE COVAD E-SURVEY.
Grignaschi S; Cavagna L; Kim M; R N; Lilleker JB; Sen P; Agarwal V; Kardes S; Day J; Makol A; Milchert M; Gheita TA; Salim B; Velikova T; Gracia-Ramos AE; Parodis I; Selva-O'callaghan A; Nikiphorou E; Chatterjee T; Tan AL; Saavedra MA; Shinjo SK; Ziade N; Knitza J; Kuwana M; Nune A; Distler O; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2022;81:334-336
COVID-19 SEVERITY AND VACCINE BREAKTHROUGH INFECTIONS IN IDIOPATHIC INFLAMMATORY MYOPATHIES, OTHER SYSTEMIC AUTOIMMUNE AND INFLAMMATORY DISEASES, AND HEALTHY INDIVIDUALS: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY.
Gupta L; Hoff LS; R N; Sen P; Katsuyuki Shinjo S; Day J; Lilleker JB; Agarwal V; Kardes S; Kim M; Makol A; Milchert M; Gheita TA; Salim B; Velikova T; Gracia-Ramos AE; Parodis I; Selva-O'callaghan A; Nikiphorou E; Chatterjee T; Tan AL; Nune A; Cavagna L; Saavedra MA; Ziade N; Knitza J; Kuwana M; Distler O; Chinoy H; Agarwal V; Aggarwal R
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2022;81:1402
OBESITY AND TOBACCO SMOKING ARE INDEPENDENTLY ASSOCIATED WITH POOR PATIENT-REPORTED OUTCOMES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM A SWEDISH TERTIARY REFERRAL CENTRE
Gomez A; Parodis I; Sjowall C
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2022;81:105-106
TREATMENT PATTERNS OF IDIOPATHIC INFLAMMATORY MYOPATHIES: RESULTS FROM AN INTERNATIONAL COHORT OF OVER 1,400 PATIENTS
Aoude M; Gupta L; Hmamouchi I; Grignaschi S; Cavagna L; Kim M; R N; Lilleker JB; Sen P; Agarwal V; Kardes S; Day J; Makol A; Milchert M; Gheita TA; Salim B; Velikova T; Gracia-Ramos AE; Parodis I; Selva-O'callaghan A; Nikiphorou E; Chatterjee T; Tan AL; Saavedra MA; Shinjo SK; Knitza J; Kuwana M; Nune A; Distler O; Chinoy H; Agarwal V; Aggarwal R; Ziade N
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2022;81:966-967
COVID-19 VACCINATION-RELATED ADVERSE EVENTS AMONG AUTOIMMUNE DISEASE PATIENTS: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY
Sen P; R N; Nune A; Lilleker JB; Agarwal V; Kardes S; Kim M; Day J; Milchert M; Gheita TA; Salim B; Velikova T; Gracia-Ramos AE; Parodis I; Selva-O'callaghan A; Nikiphorou E; Chatterjee T; Tan AL; Cavagna L; Saavedra MA; Shinjo SK; Ziade N; Knitza J; Kuwana M; Distler O; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2022;81:720-722
IMPAIRED PROMIS PHYSICAL FUNCTION IN IDIOPATHIC INFLAMMATORY MYOPATHY PATIENTS: RESULTS FROM THE MULTICENTER COVAD PATIENT REPORTED E-SURVEY
Yoshida A; Kim M; Kuwana M; R N; Lilleker JB; Sen P; Agarwal V; Kardes S; Day J; Makol A; Milchert M; Gheita TA; Salim B; Velikova T; Gracia-Ramos AE; Parodis I; Selva-O'callaghan A; Nikiphorou E; Chatterjee T; Tan AL; Nune A; Cavagna L; Saavedra MA; Katsuyuki Shinjo S; Ziade N; Knitza J; Distler O; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2022;81:1098-1099
SYSTEMATIC LITERATURE REVIEW TO INFORM THE EULAR TASK FORCE FOR RECOMMENDATIONS/POINTS TO CONSIDER FOR THE NON-PHARMACOLOGICAL MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND SYSTEMIC SCLEROSIS
Parodis I; Gomez A; Tsoi A; Chow JW; Pezzella D; Girard C; Stamm T; Bostrom C
Editorial comment: LANCET RHEUMATOLOGY. 2022;4(3):E157-E159
Patient-reported outcomes with anifrolumab in patients with systemic lupus erythematosus
Stamm T; Parodis I; Studenic P
Review: CURRENT OPINION IN RHEUMATOLOGY. 2022;34(2):139-149
Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: current insights
Lindblom J; Mohan C; Parodis I
Review: ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS. 2022;70(1):8
Treat-to-Target in Lupus Nephritis. What is the Role of the Repeat Kidney Biopsy?
Parodis I; Tamirou F; Houssiau FA
Review: JOURNAL OF CLINICAL MEDICINE. 2022;11(2):340
Patient-Reported Outcomes in Systemic Lupus Erythematosus. Can Lupus Patients Take the Driver's Seat in Their Disease Monitoring?
Parodis I; Studenic P
Review: FRONTIERS IN MEDICINE. 2022;9:952304
B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools
Parodis I; Gatto M; Sjowall C
Editorial comment: FRONTIERS IN IMMUNOLOGY. 2022;13:962088
Editorial: Clinical, Molecular and Adverse Responses to B-Cell Therapies in Autoimmune Disease
Sciascia S; Parodis I; Karim MY
Editorial comment: ANNALS OF THE RHEUMATIC DISEASES. 2022;81(1):15-19
From sequential to combination and personalised therapy in lupus nephritis: moving towards a paradigm shift?
Parodis I; Houssiau FA
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2022;74:4151-4152
Drug Repurposing for Treating Lupus Nephritis Based on Transcriptome Profiling and Autoimmunity-Related Serological Markers
Parodis I; Lindblom J; Toro-Dominguez D; Carnero-Montoro E; Borghi MO; Castillo J; Enman Y; Mohan C; Alarcon-Riquelme M; Barturen G
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2022;74:4417-4418
Transcriptome Profiling and Autoimmunity-related Serological Markers Identify Tumour Protein P53 and Complement C3a Receptor 1 as Drug Targets in Neuropsychiatric Systemic Lupus Erythematosus
Lindblom J; Toro-Dominguez D; Carnero-Montoro E; Orietta Borghi M; Castillo J; Iacobaeus E; Enman Y; Mohan C; Alarcon-Riquelme M; Barturen G; Parodis I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2022;74:332-336
COVID-19 Vaccination-related Short-term Adverse Events in Patients with Idiopathic Inflammatory Myositis and Autoimmune Multimorbidity: Results from the COVID-19 Vaccination in Autoimmune Diseases Survey
Dey M; Naveen R; Nikiphorou E; Sen P; Lilleker JB; Agarwal V; Kardes S; Day J; Milchert M; Joshi M; Gheita TA; Salim B; Velikova T; Edgar Gracia-Ramos A; Parodis I; Selva O'Callaghan A; Kim M; Chatterjee T; Tan AL; Makol A; Nune A; Cavagna L; Saavedra Salinas MA; Shinjo S; Ziade N; Knitza J; Kuwana M; Distler O; Chinoy H; Pauling J; Wincup C; Agarwal V; Aggarwal R; Gupta L
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2022;74:3018-3021
Breakthrough Infections in COVID-19 Vaccinated Patients with Systemic Sclerosis: A Survival Analysis from a Multicenter International Patient-Reported Survey
Ahmed S; Naveen R; Pauling J; Thakare D; Wincup C; Del Papa N; Sambataro G; Atzeni F; Parisi S; Govoni M; Bocci EB; Sebastiani GD; Fusaro E; Sebastiani M; Quartuccio L; Franceschini F; Sainaghi PP; Orsolini G; De Angelis R; Danielli MG; Venerito V; Sen P; Kim M; Gracia-Ramos AE; Yoshida A; Lilleker JB; Agarwal V; Kardes S; Day J; Joshi M; Milchert M; Gheita TA; Salim B; Parodis I; Selva O'Callaghan A; Nikiphorou E; Chatterjee T; Tan AL; Nune A; Cavagna L; Shinjo S; Ziade N; Knitza J; Chinoy H; Distler O; Kuwana M; Aggarwal R; Gupta L; Agarwal V; Makol A
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2022;74:1926-1928
Low-dose Belimumab and Antimalarial Agents Prevent Renal Flares in Systemic Lupus Erythematosus: Results from Four Randomised Clinical Trials
Gomez A; Jagerback S; Sjowall C; Parodis I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2022;74:2094-2098
Short-term Safety of COVID-19 Vaccination in Systemic Sclerosis Patients: Report from a Global Patient-Reported E-survey
Thakare D; Naveen R; Pauling J; Ahmed S; Wincup C; Del Papa N; Sambataro G; Atzeni F; Govoni M; Parisi S; Bocci EB; Sebastiani GD; Fusaro E; Sebastiani M; Quartuccio L; Franceschini F; Sainaghi PP; Orsolini G; De Angelis R; Danielli MG; Venerito V; Sen P; Kim M; Gracia-Ramos AE; Yoshida A; Lilleker JB; Agarwal V; Kardes S; Day J; Milchert M; Joshi M; Gheita TA; Salim B; Parodis I; Selva O'Callaghan A; Nikiphorou E; Chatterjee T; Tan AL; Nune A; Cavagna L; Shinjo S; Ziade N; Knitza J; Chinoy H; Distler O; Kuwana M; Aggarwal R; Gupta L; Agarwal V; Makol A
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2022;74:4115-4120
COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Systemic Lupus Erythematosus
Naveen R; Nikiphorou E; Joshi M; Sen P; Agarwal V; Kardes S; Lilleker JB; Chinoy H; Distler O; Kim M; Tan AL; Shinjo S; Salim B; Gheita TA; Ziade N; Velikova T; Chatterjee T; Nune A; Milchert M; Gracia-Ramos AE; O'Callaghan AS; Salinas MAS; Cavagna L; Kuwana M; Knitza J; Day J; Makol A; Aggarwal R; Agarwal V; Gupta L; Traboco LS; Parodis I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2022;74:1090-1093
Evaluation of Traditional Laboratory Markers as Predictors of Renal Flares: A Post-hoc Analysis of Four Phase III Clinical Trials of SLE
Jagerback S; Gomez A; Parodis I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2022;74:3717-3720
Vaccine Hesitancy Among Patients with Idiopathic Inflammatory Myopathies and Rheumatic Diseases in 2021-2022: A Comparative Analysis of COVID-19 Vaccination in Autoimmune Diseases Surveys
Naveen R; Joshi M; Sen P; Agarwal V; Shinjo S; Kardes S; Lilleker JB; Chinoy H; Makol A; Distler O; Kim M; Nikiphorou E; Tan AL; Salim B; Gheita TA; Ziade N; Velikova T; Chatterjee T; Nune A; Milchert M; Parodis I; Edgar Gracia-Ramos A; Selva O'Callaghan A; Saavedra Salinas MA; Cavagna L; Kuwana M; Knitza J; Day J; Toro Gutierrez CE; Caballero C; Dey D; Zamora Tehozol E; Rojas Serrano J; Garcia-De La Torre I; Colunga I; Merayo-Chalico J; Pauling J; Wincup C; Gasparyan AY; Agarwal V; Aggarwal R; Gupta L
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2022;74:1768-1772
COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Rheumatoid Arthritis
Naveen R; Parodis I; Joshi M; Sen P; Kim M; Agarwal V; Kardes S; Lilleker JB; Chinoy H; Distler O; Tan AL; Shinjo S; Salim B; Gheita TA; Ziade N; Velikova T; Chatterjee T; Nune A; Milchert M; Gracia-Ramos AE; O'Callaghan AS; Salinas MAS; Cavagna L; Kuwana M; Knitza J; Day J; Makol A; Pauling J; Wincup C; Tehozol EZ; Serrano JR; Garcia-De La Torre I; Aggarwal R; Agarwal V; Gupta L; Nikiphorou E
Review: NATURE REVIEWS RHEUMATOLOGY. 2022;18(1):9-21
Differentiating between UCTD and early-stage SLE: from definitions to clinical approach
Sciascia S; Roccatello D; Radin M; Parodis I; Yazdany J; Pons-Estel G; Mosca M
Review: JOURNAL OF CLINICAL MEDICINE. 2021;10(16):3566
Fatigue in Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Comparison of Mechanisms, Measures and Management
Dey M; Parodis I; Nikiphorou E
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2021;80(7):e119
How to use the Lupus Low Disease Activity State (LLDAS) in clinical trials
Parodis I; Nikpour M
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2021;80:643
MYOCARDIAL INFARCTIONS, SUBTYPES, LOCATIONS AND CORONARY ATHEROSCLEROSIS IN SLE - A COMPARATIVE STUDY WITH MATCHED CONTROLS
Samuelsson I; Parodis I; Gunnarsson I; Zickert A; Hofman-Bang C; Wallen H; Svenungsson E
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2021;73:2699-2700
Associations Between Early Changes in Circulating B Cell Subsets and Severe Flare in Systemic Lupus Erythematosus -Results from Three Phase III Trials of Belimumab
Parodis I; Gomez A; Lindblom J; Borg A; Emamikia S; Gatto M
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2021;73:2695-2696
Early Increase in Circulating Memory B Cells Portends Clinical Response to Treatment in Pooled Data from Three Phase III Trials of Belimumab
Parodis I; Gomez A; Lindblom J; Borg A; Emamikia S; Gatto M
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2021;73:2604-2606
The Impact of Remission and Low Disease Activity Attainment on Health-related Quality of Life in Two Phase III Clinical Trials of Belimumab in Systemic Lupus Erythematosus
Emamikia S; Oon S; Gomez A; Lindblom J; Borg A; Enman Y; Morand E; Grannas D; van Vollenhoven R; Nikpour M; Parodis I
Conference publication: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2021;50:45-46
Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus
Gomez A; Butrus FH; Johansson P; Akerstrom E; Soukka S; Komujuni SK; Enman Y; Pettersson S; Parodis I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2021;73:2586-2588
Serum B Cell Activating Factor Reflects Good EULAR Response to TNF Inhibition in Patients with Rheumatoid Arthritis
Hernandez-Breijo B; Parodis I; Plasencia-Rodriguez C; Diaz-Almiron M; Martinez-Feito A; Novella-Navarro M; Pascual-Salcedo D; Balsa A
Conference publication: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2021;50:1-2
THURSDAY SESSION Abstracts
Parodis I; Adamichou C; Aydin S; Gomez A; Demoulin N; Weinmann-Menke J; Houssiau FA; Tamirou F
Conference publication: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2021;50:41-42
De novo lupus nephritis in patients receiving belimumab therapy
Parodis I; Vital EM; Jonsen A; Hassan SU; Leonard D; Eriksson P; Bengtsson AA; Gunnarsson I; Ronnblom L; Sjowall C
Review: CURRENT VASCULAR PHARMACOLOGY. 2020;18(6):549-565
Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and Prevention
Kostopoulou M; Nikolopoulos D; Parodis I; Bertsias G
Preprint: RESEARCH SQUARE. 2020
BAFF Predicts Immunogenicity in Older Patients With Rheumatoid Arthritis Treated With TNF Inhibitors
Hernández-Breijo B; Navarro-Compán V; Plasencia-Rodríguez C; Parodis I; Gehin JE; Martínez-Feito A; Novella-Navarro M; Mezcua A; Warren DJ; Nozal P; Pascual-Salcedo D; Balsa A
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2020;79:664-665
ASSOCIATION OF OVERWEIGHT/OBESITY WITH IMPAIRED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Gomez A; Butrus FH; Johansson P; Akerstrom E; Soukka S; Emamikia S; Enman Y; Pettersson S; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2020;79:297
BAFF CONTRIBUTES TO THE DEVELOPMENT OF IMMUNOGENICITY IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TNF INHIBITORS
Hernandez-Breijo B; Parodis I; Gehin J; Plasencia C; Navarro-Compan V; Martinez-Feito A; Warren DJ; Mezcua A; Novella-Navarro M; Nozal P; Balsa A
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2020;79:102-103
2019 UPDATE OF THE JOINT EUROPEAN LEAGUE AGAINST RHEUMATISM AND EUROPEAN RENAL ASSOCIATION-EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION (EULAR/ERA-EDTA) RECOMMENDATIONS FOR THE MANAGEMENT OF LUPUS NEPHRITIS
Fanouriakis A; Kostopoulou M; Cheema K; Anders HJ; Aringer M; Bajema I; Boletis JN; Frangou E; Houssiau F; Hollis J; Karras A; Marchiori F; Marks S; Moroni G; Mosca M; Parodis I; Praga M; Schneider M; Smolen JS; Tesar V; Trachana M; Vollenhoven RV; Voskuyl A; Teng YKO; Van Leeuw B; Bertsias G; Jayne D; Boumpas D
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2020;79:347
GLOMERULAR AND TUBULOINTERSTITIAL LESIONS IN PER-PROTOCOL REPEAT BUT NOT BASELINE KIDNEY BIOPSY PORTEND RELAPSE AND LONG-TERM RENAL FUNCTION IMPAIRMENT, RESPECTIVELY, IN INCIDENT CASES OF PROLIFERATIVE LUPUS NEPHRITIS
Parodis I; Adamichou C; Aydin S; Gomez A; Demoulin N; Weinmann-Menke J; Houssiau F; Tamirou F
Review: ANNALS OF THE RHEUMATIC DISEASES. 2020;79(6):713-723
2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis
Fanouriakis A; Kostopoulou M; Cheema K; Anders H-J; Aringer M; Bajema I; Boletis J; Frangou E; Houssiau FA; Hollis J; Karras A; Marchiori F; Marks SD; Moroni G; Mosca M; Parodis I; Praga M; Schneider M; Smolen JS; Tesar V; Trachana M; van Vollenhoven RF; Voskuyl AE; Teng YKO; van Leew B; Bertsias G; Jayne D; Boumpas DT
Conference publication: LUPUS SCIENCE & MEDICINE. 2020;7(Suppl 1):a106
P156 Accelerated coronary atherosclerosis – a major cause of myocardial infarction in systemic lupus erythematosus
Samuelsson I; Parodis I; Gunnarsson I; Zickert A; Hofman-Bang C; Wallén H; Svenungsson E
Conference publication: LUPUS SCIENCE & MEDICINE. 2020;7(Suppl 1):a113
P170 Antimalarial agent use is associated with favourable physical functioning in patients with systemic lupus erythematosus
Parodis I; Soukka S; Gomez A; Enman Y; Johansson P; Emamikia S; Chatzidionysiou K
Conference publication: LUPUS SCIENCE & MEDICINE. 2020;7(Suppl 1):a44
P33 Cytokine and autoantibody profiles during treatment with belimumab in patients with systemic lupus erythematosus
Parodis I; Åkerström E; Sjöwall C; Sohrabian A; Jönsen A; Gomez A; Frodlund M; Zickert A; Bengtsson AA; Rönnelid J; Gunnarsson I
Conference publication: LUPUS SCIENCE & MEDICINE. 2020;7(Suppl 1):a96
P137 De novo lupus nephritis during belimumab treatment
Parodis I; Vital EM; Jönsen A; Hassan S-U; Leonard D; Eriksson P; Bengtsson AA; Gunnarsson I; Rönnblom L; Sjöwall C
Conference publication: LUPUS SCIENCE & MEDICINE. 2020;7(Suppl 1):a26
O33 Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis
Parodis I; Adamichou C; Aydin S; Gomez A; Demoulin N; Weinmann-Menke J; Houssiau FA; Tamirou F
Review: FRONTIERS IN MEDICINE. 2020;7:316
B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice
Parodis I; Stockfelt M; Sjowall C
Review: LUPUS SCIENCE & MEDICINE. 2020;7(1):e000389
Prediction of prognosis and renal outcome in lupus nephritis
Parodis I; Tamirou F; Houssiau FA
Letter: AUTOIMMUNITY REVIEWS. 2019;18(10):102372
Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus
Hernandez-Breijo B; Gomez A; Soukka S; Johansson P; Parodis I
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2019;78(7):1006-1007
Established organ damage reduces belimumab efficacy in systemic lupus erythematosus
Parodis I; Gomez A; Emamikia S; Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:777-778
ANTIMALARIAL AGENTS DIMINISH WHILE METHOTREXATE, AZATHIOPRINE AND MYCOPHENOLIC ACID INCREASE BAFF LEVELS IN SYSTEMIC LUPUS ERYTHEMATOSUS
Hernandez-Breijo B; Gomez A; Soukka S; Johansson P; Parodis I
Review: AUTOIMMUNITY REVIEWS. 2019;18(6):615-620
G-CSF-induced aortitis: Two cases and review of the literature
Parodis I; Dani L; Notarnicola A; Martenhed G; Fernstrom P; Matikas A; Wiklander OPB
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:781-782
ANTIMALARIAL AGENTS IMPROVE PHYSICAL FUNCTIONING IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Parodis I; Soukka S; Gomez A; Enman Y; Johansson P; Emamikia S; Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:761
PREDICTORS OF LOW DISEASE ACTIVITY AND CLINICAL REMISSION FOLLOWING BELIMUMAB TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS
Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K
Conference publication: 2019;:a107.1-a1a107
148 Antimalarial agents and other immunosuppressants influence BAFF levels in opposite directions in patients with systemic lupus erythematosus
Hernandez-Breijo B; Gomez A; Johansson P; Soukka S; Parodis I
Conference publication: 2019;:a108
150 Antimalarial agents improve physical functioning in patients with systemic lupus erythematosus
Parodis I; Soukka S; Gomez A; Johansson P; Emamikia S; Enman Y; Chatzidionysiou K
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2019;71
Antimalarial Agents Improve Physical Functioning in Patients with Systemic Lupus Erythematosus
Parodis I; Soukka S; Gomez A; Enman Y; Johansson P; Emamikia S; Chatzidionysiou K
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2019;71
Cytokine and Autoantibody Profiles During Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
Parodis I; Akerstrom E; Sjowall C; Sohrabian A; Jonsen A; Gomez A; Frodlund M; Zickert A; Bengtsson A; Ronnelid J; Gunnarsson I
Preprint: ZAPPYLAB, INC.. 2018
Serum soluble (s)Axl assay protocol v1
Parodis I; Ding H; Mohan C; Gunnarsson I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2018;77:691
FRI0309 The impact of belimumab and rituximab on health-related quality of life in patients with systemic lupus erythematosus
Parodis I; Benavides AHL; Zickert A; Pettersson S; Möller S; Henriksson EW; Voss A; Gunnarsson I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2018;77:1414-1415
AB0512 Occurrence and consequences of anti-drug antibodies to rituximab in systemic lupus erythematosus
Faustini F; Parodis I; Dunn N; Ryner M; Fogdell-Hahn A; Gunnarsson I
Conference publication: 2018;:a101.2-a1a102
PS7:134 Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus – distinct roles of baff and april
Parodis I; Söder F; Faustini F; Kasza Z; Wermeling F; Gunnarsson I
Conference publication: 2018;:a100.3-a1a101
PS7:132 Smoking reduces the efficacy of belimumab in mucocutaneous lupus
Parodis I; Gomez A; Sjöwall C; Jönsen A; Zickert A; Frodlund M; Bengtsson A; Gunnarsson I
Conference publication: 2018;:a111.2-a1a113
PS8:153 Subtypes and location of myocardial infarctions in systemic lupus erythematosus
Samuelsson I; Parodis I; Anan C
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2018;70
SLE Patients with No Organ Damage Might Benefit More from Belimumab Treatment
Parodis I; Emamikia S; Gomez A; Chatzidionysiou K
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2018;70
Clinical SLE Disease Activity Index Score of Zero May be a More Pragmatic Outcome Measure in SLE Studies
Parodis I; Emamikia S; Gunnarsson I; van Vollenhoven RF; Chatzidionysiou K
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2018;70
A Role of Vascular Cell Adhesion Molecule 1 and Activated Leukocyte Cell Adhesion Molecule in Lupus Nephritis
Parodis I; Gokaraju S; Zickert A; Zhang T; Habazi D; Larsson A; Svenungsson E; Mohan C; Gunnarsson I
Conference publication: JOURNAL OF IMMUNOLOGY. 2018;200(1)
ALCAM and VCAM-1 as potential urinary biomarkers in Caucasian lupus patients
Habazi D; Vanarsa K; Stanley S; Gokaraju S; Ding H; Parodis I; Gunnarsson I; Mohan C
Preprint: JMIR PREPRINTS. 2017
Increasing Reasoning Awareness: Video Analysis of Students� Two-Party Virtual Patient Interactions
Edelbring S; Parodis I; Lundberg IE
Preprint: JMIR PREPRINTS. 2017
Increasing Reasoning Awareness: Video Analysis of Students� Two-Party Virtual Patient Interactions (Preprint)
Edelbring S; Parodis I; Lundberg IE
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2017;76:864
LATE-ONSET NEUTROPENIA FOLLOWING RITUXIMAB TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS - A ROLE OF THE BAFF/APRIL PATHWAY
Parodis I; Soder F; Faustini F; Wermeling F; van Vollenhoven RF; Svenungsson E; Gunnarsson I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2017;76:861-862
HIGH ANTI-DSDNA CONTENT IN SLE IMMUNE COMPLEXES IS ASSOCIATED WITH CLINICAL REMISSION FOLLOWING BELIMUMAB TREATMENT
Sohrabian A; Parodis I; Carlstromer-Berthen N; Sjowall C; Jonsen A; Zickert A; Frodlund M; Bengtsson A; Gunnarsson I; Ronnelid J
Review: AUTOIMMUNITY REVIEWS. 2017;16(4):343-351
Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus
Parodis I; Sjowall C; Jonsen A; Ramskold D; Zickert A; Frodlund M; Sohrabian A; Arnaud L; Ronnelid J; Malmstrom V; Bengtsson AA; Gunnarsson I
Conference publication: LUPUS SCIENCE & MEDICINE. 2017;4(Suppl 1):a44-A45
104 A mass cytometry (CYTOF) approach to study B cell alterations during baff blockade treatment with belimumab in systemic lupus erythematosus
Parodis I; Ramsköld D; Tadepally L; Chen Y; Zickert A; Mikes J; Amara K; Achour A; Brodin P; Gunnarsson I; Malmström V
Conference publication: LUPUS SCIENCE & MEDICINE. 2017;4(Suppl 1):a43-A44
103 Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus
Parodis I; Sjöwall C; Jönsen A; Ramsköld D; Zickert A; Frodlund M; Sohrabian A; Arnaud L; Rönnelid J; Malmström V; Bengtsson A; Gunnarsson I
Doctoral thesis: 2017
Systemic lupus erythematosus : biomarkers and biologics
Parodis, Ioannis
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:1063
SERUM FERRITIN AS A BIOMARKER OF CLINICAL AND HISTOPATHOLOGICAL RESPONSE TO TREATMENT IN LUPUS NEPHRITIS
Parodis I; Ding H; Zickert A; Arnaud L; Mohan C; Gunnarsson I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:547
SERUM INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 2 (IGFBP2) AS A BIOMARKER OF CLINICAL AND HISTOPATHOLOGICAL TREATMENT RESPONSE IN LUPUS NEPHRITIS
Parodis I; Ding H; Zickert A; Arnaud L; Mohan C; Gunnarsson I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2016;68
Observations of Early and Late B Cell Alterations during Belimumab Treatment in Patients with Systemic Lupus Erythematosus Using Mass Cytometry (CyTOF)
Parodis I; Ramskold D; Brodin P; Zickert A; Tadepally L; Chen Y; Mikes J; Achour A; Gurmarsson I; Malmstrom V
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2016;68
High Baseline B Lymphocyte Stimulator (BLyS) Levels Predict Response While Smoking and Organ Damage at Baseline Predict Failure to Belimumab in Three Swedish Clinical Practice Settings
Parodis I; Sjowall C; Jonsen A; Zickert A; Ramskold D; Frodlund M; Arnaud L; Malmstrom V; Bengtsson AA; Gunnarsson I
Conference publication: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2016;34(4):S69
SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 2 (STNFR2) AS A BIOMARKER OF KIDNEY TISSUE DAMAGE AND LONG-TERM RENAL OUTCOME IN LUPUS NEPHRITIS
Parodis I; Ding H; Zickert A; Arnaud L; Svenungsson E; Mohan C; Gunnarsson I
Conference publication: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2016;45:42
Soluble tumour necrosis factor receptor 2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis
Parodis I; Ding H; Zickert A; Arnaud L; Svenungsson E; Mohan C; Gunnarsson I
Conference publication: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2016;34(4):S75
SERUM FERRITIN AS A MARKER OF CLINICAL AND HISTOPATHOLOGICAL RESPONSE TO TREATMENT IN LUPUS NEPHRITIS
Parodis I; Ding H; Zickert A; Arnaud L; Mohan C; Gunnarsson I
Conference publication: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2016;34(4):S69
SERUM ANEXELEKTO (AXL) AS A NOVEL BIOMARKER OF RENAL ACTIVITY, TREATMENT RESPONSE AND LONG-TERM OUTCOME IN PATIENTS WITH LUPUS NEPHRITIS
Parodis I; Ding H; Zickert A; Arnaud L; Mohan C; Gunnarsson I
Conference publication: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2016;34(4):S69-S70
SERUM INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 2 (IGFBP2) AS A BIOMARKER OF CLINICAL AND HISTOPATHOLOGICAL TREATMENT RESPONSE IN LUPUS NEPHRITIS
Parodis I; Ding H; Zickert A; Arnaud L; Mohan C; Gunnarsson I
Conference publication: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2016;45:40-41
Serum ferritin as a marker of clinical and histopathological response to treatment in lupus nephritis
Parodis I; Ding H; Zickert A; Arnaud L; Mohan C; Gunnarsson I
Conference publication: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2016;45:43
Serum insulin-like growth factor-binding protein 2 (IGFBP2) as a biomarker of clinical and histopathological treatment response in lupus nephritis
Parodis I; Ding H; Zickert A; Arnaud L; Mohan C; Gunnarsson I
Conference publication: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2016;45:43-44
Serum anexelekto (Axl) as a novel biomarker of renal activity, treatment response, and long-term outcome in patients with lupus nephritis
Parodis I; Ding H; Zickert A; Arnaud L; Mohan C; Gunnarsson I
Conference publication: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2016;34(4):S18
ANTIPHOSPHOLIPID ANTIBODIES IN LUPUS NEPHRITIS
Parodis I; Arnaud L; Gerhardsson J; Zickert A; Sundelin B; Malmstrom V; Svenungsson E; Gunnarsson I
Conference publication: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2016;45:41-42
Antiphospholipid antibodies in lupus nephritis
Parodis I; Arnaud L; Gerhardsson J; Zickert A; Sundelin B; Malmstrom V; Svenungsson E; Gunnarsson I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2015;74:804
ANTIPHOSPHOLIPID ANTIBODIES IN LUPUS NEPHRITIS AND THEIR ROLE IN LONG-TERM OUTCOME
Parodis I; Svenungsson E; Gerhardsson J; Zickert A; Malmstrom V; Gunnarsson I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2015;67
Decreased Disease Activity and Corticosteroid Usage and Improved Quality of Life during Belimumab Treatment in Patients with Systemic Lupus Erythematosus - a Prospective Real-Life Observational Study
Parodis I; Sjowall C; Jonsen A; Zickert A; Frodlund M; Ramskold D; Bengtsson AA; Gunnarsson I
Conference publication: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2015;33(3):S35
Decreased disease activity and corticosteroid usage and improved quality of life during belimumab treatment in patients with systemic lupus erythematosus - a prospective real-life observational study
Parodis I; Sjowall C; Jonsen A; Frodlund M; Ramskold D; Bengtsson A; Gunnarsson I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2015;67
Late-Onset Neutropenia Following Rituximab Treatment in Patients with Systemic Lupus Erythematosus
Parodis I; Soder F; van Vollenhoven RF; Svenungsson E; Gunnarsson I
Conference publication: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2015;33(3):S29
Late-onset neutropenia following rituximab treatment in patients with systemic lupus erythematosus
Parodis I; Soder F; van Vollenhoven R; Svenungsson E; Gunnarsson I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2015;67
Serum Axl and Tumor Necrosis Factor Receptor II Portend Long-Term Renal Outcome in Lupus Nephritis
Parodis I; Ding H; Zickert A; Mohan C; Gunnarsson I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2015;67
Serum Ferritin and Insulin-like Growth Factor-Binding Protein 2 As Biomarkers of Clinical and Histopathological Treatment Response in Lupus Nephritis
Parodis I; Ding H; Zickert A; Mohan C; Gunnarsson I
Conference publication: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2015;33(3):S16
Antiphospholipid antibodies in lupus nephritis and their role in long-term renal outcome
Parodis I; Svenungsson E; Gerhardsson J; Zickert A; Malmstrom V; Gunnarsson I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2014;73:968
DECREASED SLE DISEASE ACTIVITY AND CORTICOSTEROID USAGE AND NO RENAL FLARES DURING BELIMUMAB TREATMENT
Parodis I; Svenungsson E; Axelsson M; Gunnarsson I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2014;73:363
INTERFERON (IFN)-LAMBDA1/3, BUT NOT IFN-ALPHA, IS A MARKER OF POOR RESPONSE TO TREATMENT IN LUPUS NEPHRITIS
Zickert A; Oke V; Parodis I; Svenungsson E; Gunnarsson I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2014;73:366
BLYS AND APRIL IN LUPUS NEPHRITIS: CORRELATIONS WITH SEROLOGY - BLYS AS A NON-INVASIVE PREDICTOR OF RESPONSE
Parodis I; Zickert A; Axelsson M; Svenungsson E; Malmstrom V; Gunnarsson I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2014;66:S292
Decreased Disease Activity and Corticosteroid Usage and No Renal Flares during Belimumab Treatment in Patients with Systemic Lupus Erythematosus
Parodis I; Svenungsson E; Axelsson M; Gunnarsson I
Conference publication: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2014;43:90-91
Decreased disease activity and corticosteroid usage and no renal flares during belimumab treatment in patients with systemic lupus erythematosus
Parodis I; Svenungsson E; Axelsson M; Gunnarsson I
Conference publication: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2014;43:10
Interferon (IFN)-λ1/3, but not IFN-α, is a marker of poor response to treatment in lupus nephritis
Zickert A; Oke V; Parodis I; Svenungsson E; Gunnarsson I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2013;72:A34
DISAPPEARANCE AND REAPPEARANCE OF IGG, IGA AND IGM AUTOANTIBODY ISOTYPES AND IMMUNE COMPLEXES IN RITUXIMAB-TREATED SLE PATIENTS
Persson B; McAree F; Muller M; Trollmo T; Parodis I; Jonsdottir T; Malmstrom V; Gunnarsson I; Ronnelid J
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2013;65:S1197
B-Lymphocyte Stimulator and A Proliferation Inducing Ligand In Lupus Nephritis: Low Serum Levels Of BLyS Predict Treatment Response
Parodis I; Zickert A; Svenungsson E; Malmstrom V; Gunnarsson I
Show more

Employments

Adjunct Lecturer, Department of Medicine, Karolinska Institutet, 2020-2026

Degrees and Education

Docent, Karolinska Institutet, 2021
Degree Of Doctor Of Philosophy, Department of Medicine, Solna, Karolinska Institutet, 2017

About me

Research

Teaching

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI